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ABSTRACT 
Fatima Manzoor: Tissue-specific cytokine-based immunotherapy to treat type 1 diabetes 
(Under the direction of Roland M. Tisch) 
Type 1 diabetes (T1D) is characterized by the T cell-mediated destruction of the 
insulin-producing β cells. Progressive loss of β cell mass results in the inability to control 
blood glucose levels, leading to hyperglycemia. Although other immune cells such as B cells, 
dendritic cells (DC), and macrophages also contribute to β cell destruction, the anti-islet 
autoimmune response is driven primarily by pathogenic effector T cells (Teff). Maintaining a 
balance between Teff and suppressive Foxp3-expressing regulatory T cells (Foxp3+Treg) is 
important in preserving self-tolerance in the periphery. In T1D, the inflammatory response in 
the islets is skewed towards proliferation and survival of pathogenic Teff, due in part to 
defects within Foxp3+Treg. To reestablish tolerance and suppress the autoimmune response, 
the Foxp3+Treg pool needs to be augmented, both qualitatively and quantitatively.  
Our first study describes the role of IL-35 in suppressing autoreactive Teff in pre-
diabetic NOD mice. Ectopically expressing IL-35 using an adeno-associated virus (AAV) 
vector protected NOD female mice at a late preclinical T1D stage from diabetes onset. This 
protection from diabetes was characterized by a reduction in overall islet conventional T cell 
numbers and proliferative status, as well as a reduction in islet-resident DC and IFNγ-
producing CD4+ Teff. Although protection from disease was not due to an increase in islet 
Foxp3+Treg, ectopic IL-35 induced a qualitatively distinct pool of Foxp3+Treg marked by 
high expression of cytotoxic-lymphocyte antigen-4 (CTLA-4), a molecule necessary for 
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contact-mediated suppression. Importantly, we found that using a pancreas-tropic capsid 
serotype of AAV restricted the potent suppressive function of IL-35 to Teff in the islets; 
making it a promising immunotherapy tool to treat T cell mediated immune disorders, 
including T1D.  
The aim of our second study was to establish an approach to enhance human 
FOXP3+Treg in a tissue-specific manner. Reports demonstrate that FOXP3+Treg derived 
from T1D patients exhibit various defects, and sensitivity of T1D-derived Teff to 
FOXP3+Treg-mediated suppression is reduced. Accordingly, we determined whether ectopic 
human IL-2 expression using AAV gene transfer expands FOXP3+Treg in humanized mice 
engrafted with T1D and non-T1D-derived T cells. NOD.RagnullIL2rγnull (NRG) mice injected 
with PBMC derived from T1D and non-diabetic (ND) donors were readily reconstituted with 
human CD4+ and CD8+ T cells, and β cell-specific human IL-2 increased pancreatic 
FOXP3+Treg in both T1D and non-T1D-derived humanized mice. 
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CHAPTER 1: INTRODUCTION  
1.1 Type 1 diabetes mellitus 
Type 1 diabetes (T1D) is one of more than 80 autoimmune diseases affecting millions 
of people worldwide. Although T1D is prevalent among all ethnic populations, a marked rise 
in North America and other Western nations has been detected [1, 2]. T1D is manifested 
following an interplay between genetic susceptibility and ill-defined environmental triggers.  
The latter is highlighted by discordance among monozygotic twins and the development of 
T1D [3]. T1D results from the destruction of insulin-producing β cells of the islets of 
Langerhans. This β cell destruction is mediated primarily by pathogenic autoreactive T cells, 
which leads to an inability of patients with T1D to control blood glucose levels resulting in 
hyperglycemia and other co-morbidities [4]. Typically, β cell autoimmunity is initiated a 
number of years prior to the clinical onset of T1D. The latter is evident by the appearance of 
serum islet-specific autoantibodies to insulin (IAA), glutamic acid decarboxylase (GAD65), 
islet cell cytoplasm (ICA) and other β cell autoantigens in prediabetic subjects [5-9]. Most 
subjects progressing to overt diabetes present with at least two anti-islet autoantibodies [10].  
1.2 Susceptibility to T1D development 
Several genes confer susceptibility to and protection from T1D development [11, 12]. 
Animal models of T1D have aided in determining several susceptibility loci that in 
conjunction with unknown environmental and other indeterminate triggers lead to overt 
diabetes. Unlike genetic studies in the non-obese diabetic (NOD) mouse, a spontaneous 
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model of T1D that benefit from inbreeding, determining T1D susceptibility loci in humans 
has proven challenging due in part to an inability to confirm the effect(s) of implicated genes 
on mechanism of disease pathogenesis [8]. Nevertheless, studies in T1D patients and NOD 
mice have shown that the most important T1D susceptibility genes are located in the major 
histocompatibility complex (MHC) region, consistent with a critical role for T cells driving 
disease [7]. This susceptibility region is termed the IDDM1 or idd1 locus in humans and 
NOD mice, respectively [8, 13]. Although MHC loci are implicated in conferring almost 
50% of genetic susceptibility to T1D, there are more than 30 non-HLA susceptibility loci, of 
which at least 6 loci are shared between NOD mice and T1D patients [1, 4]. Genes in the 
interleukin-2 (IL-2) and IL-2 receptor (IL-2R) signaling pathway, such as CD25, a 
component of the high-affinity IL-2R, and protein tyrosine phosphatase non-receptor type 2 
(PTPN2), a negative regulator of IL-2R signaling, are examples of the various genes that 
have an impact on several aspects of immune regulation as well as β cell physiology in T1D 
[13, 14].  
The rise in T1D incidence in European and North American populations has been 
used as an argument for environmental factors driving the diabetogenic response. Studies 
exploring environmental triggers such as coxsackievirus infection, environmental toxins, and 
diet, have not yet yielded a specific culprit. Viral infection serving as a trigger for T1D 
development in susceptible individuals has been studied extensively [15]. Group B 
coxsackievirus is a pancreas-tropic enterovirus that preferentially infects pancreatic β cells 
and acinar cells, causing diabetes and pancreatitis. Coxsackievirus RNA has been isolated 
from T1D patients at various stages of disease, and has been shown to accelerate disease 
development in NOD mice [16]. Viral infection is believed to trigger T1D through at least 3 
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mechanisms: i) bystander activation of autoreactive T cells, ii) molecular mimicry where a 
viral protein similar to an islet autoantigen epitope primes β cell-specific T cells, and iii) 
direct cytolytic effects on β cells.  
An environmental influence on disease development is also mirrored in NOD mice. 
NOD mice housed in specific pathogen free (SPF) facilities exhibit a higher incidence of 
disease than NOD mice housed in conventional “dirty” facilities. Furthermore, NOD mice 
exposed to bacterial components are protected from the onset of T1D [17]. These findings 
support the “hygiene hypothesis” which postulates that exposure to immune stimuli, such as 
bacterial and viral microbes, have evolutionarily protected from T1D. Accordingly, enhanced 
sanitation and early childhood vaccination in the Western world limits the exposure to such 
stimuli, which leads to increased T1D development. Notably, NOD mice deficient for the 
Myd88 gene, which is an adaptor molecule for toll-like receptor (TLR) function following 
microbial stimuli, are protected from disease when housed in SPF facilities [18]. 
Interestingly, Myd88-deficient NOD mice housed in germ-free facilities developed disease 
similar to wild-type NOD controls, indicating a protective effect of commensal microbiota 
[18]. 
1.3 NOD mouse model of T1D 
In addition to environmental modulation of disease and genetic susceptibility loci 
discussed above, the NOD mouse model of T1D shares several characteristics of human 
disease. Hallmark of T1D pathogenesis is the infiltration, or “insulitis”, of the islets by 
immune cells, including CD4+ and CD8+ T cells, B cells, natural killer (NK) cells, dendritic 
cells (DC), and macrophages [19, 20]. In both T1D patients and NOD mice, β cell 
destruction is commensurate with a decline in insulin production and increase in immune cell 
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infiltrate. B cells, DC, and macrophages are among the first cells infiltrating the islets. The 
event that initiates trafficking of these antigen-presenting cells (APC) into the islets is 
unclear. In NOD mice remodeling of the pancreas at 2 wks of age is believed to promote 
APC infiltration of the islets, which is then followed by the appearance of pathogenic 
effector T cells (Teff) [21].  
Naïve β cell-specific T cells are first primed in the draining pancreatic lymph node 
(PLN) by DC and possibly B cells that have taken up self-antigen at and have migrated from 
the islets [22]. Pathogenic effector CD4+ and CD8+ T cells (Teff), typically exhibiting a type 
1 phenotype, marked by secretion of interferon-γ (IFNγ), then traffic to the islets and begin 
targeting the insulin-producing β cells. Initial β cell destruction is believed to be mediated by 
a few select autoantigens. However, as β cells are destroyed, additional self-antigens and 
epitopes within these proteins are targeted. This process, termed “epitope spreading”, 
amplifies the diabetogenic response eventually leading to destruction of the majority of β 
cells, and the clinical onset of T1D. CD4+ and CD8+ T cells have distinct roles in driving 
β cell destruction. Islet resident CD4+ T cells via secretion of IFNγ and TNFα establish a 
proinflammatory milieu, which further enhances recruitment of Teff and other inflammatory 
effectors. Notably, the combination of IFNγ and TNFα has cytolytic effects on β cells in 
vitro [23, 24]. On the other hand, islet resident CD8+ Teff directly kill β cells via a classical 
CTL-target-mediated interaction [25]. For instance, NOD mice deficient for β2-
microglobulin (β2m), and in which β cells lack MHC class I expression, are protected from 
T1D [26, 27]. Importance of CD4+ and CD8+ T cells in disease pathogenesis is demonstrated 
by the ability of T cells to adoptively transfer disease [28, 29]; furthermore NOD mice 
lacking either CD4+ or CD8+ T cells remain diabetes-free [27, 30].  
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1.4 Thymic development of T cells  
Immune tolerance is established through central and peripheral tolerance 
mechanisms. The thymus is the site of central tolerance, a process that ensures that self-
reactive T cell clones are purged from the T cell repertoire. Initiation of T1D is due to a loss 
of tolerance to multiple epitopes recognizing self-antigens, demonstrating a role for defective 
thymic T cell selection in conferring susceptibility to T1D. The thymus is the key site for 
development of T cells and the T cell receptor (TCR) repertoire. Two important “selection” 
processes occur in the thymus. Positive selection promotes development of T cells that 
recognize self-MHC, whereas negative selection, or clonal deletion, ensures that T cells 
bearing TCR that bind self-peptide-MHC (pMHC) complexes with moderate to high affinity 
are deleted.  
Initially, progenitors from the bone marrow enter the thymus as double negative (DN) 
thymocytes, which lack expression of both CD4 and CD8 co-receptors. As the thymocytes 
migrate through thymic microenvironments, both antigen-independent and -dependent events 
drive thymocyte development and shape the TCR repertoire. At the DN stage, thymocytes 
can either give rise to αβ or γδ T cells [31]. T cells committed to the αβ lineage require 
expression of recombination-activation gene 1 (RAG1) and RAG2 to pair TCR β with the 
pre-TCRα chain, establishing a functional pre-TCR complex [32]. αβ T cells expressing 
CD4 and CD8 make up the double positive (DP) pool.  
During thymic positive selection, DP that interact with pMHC presented by cortical 
thymic epithelial cells (cTEC) with appropriate avidity receive survival signals, traffick to 
the medulla, and mature into single-positive thymocytes (SP). DP expressing TCRs that bind 
weakly or not at all to pMHC fail to receive survival signals and undergo ‘death by neglect’. 
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Alternatively, DP that interact with pMHC with relatively high avidity undergo apoptosis and 
clonal deletion [33]. The higher the diversity of pMHC complexes presented by cTEC to DP, 
the more diverse the T cell repertoire, thereby enhancing protective immunity.  
Positively-selected SP reside in the medulla for 4-5 days, constantly sampling pMHC 
presented by medullary thymic epithelial cells (mTEC) and thymic DC [34]. Negative 
selection aims to delete SP thymocytes that are highly reactive to self-antigens. mTEC 
express peripheral tissue-specific antigens (TSAs) whose expression in the thymus is 
controlled by the Aire gene [35]. The transcription factor autoimmune regulator (AIRE) 
controls expression of islet-specific autoantigens such as insulin in the thymus [36]. In 
addition to presentation of AIRE-regulated self-antigens, SP in the medulla also recognize 
self-antigens presented by thymic CD8a+ DC and migratory DC that enter the thymus from 
the periphery and are able to present peripheral tissue or even foreign self-antigens [34, 37]. 
This high diversity of self-antigens presented to SP during residency in the medulla ensures 
that a high number of T cell-APC interactions take place to promote efficient deletion of 
autoreactive precursors. T1D susceptibility is conferred in part by specific alleles of MHC 
class II, such as IAg7 expressed by NOD mice. Evidence suggests that IAg7 binds self-
peptides poorly, which contributes to inefficient thymic negative selection [38]. Some studies 
in NOD mice have shown that SP are resistant to apoptosis, which might be due to reduced 
expression of Bim, a pro-apoptotic molecule [39, 40]. Meanwhile, other reports have 
indicated no difference in sensitivity of NOD thymocytes to apoptosis leading to a 
confounding picture of thymic selection in NOD mice [41].  
Notably, development of thymic or “natural” CD4+CD25+ Foxp3-expressing Treg 
(Foxp3+Treg) also occurs in the thymic medulla. In fact, SP interaction with mTEC and 
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thymic DC is necessary for Foxp3+Treg development. Both thymic DC and mTEC promote 
differentiation of CD4+SP into Foxp3+Treg that is mediated by intermediate to high TCR 
signaling [42]. Thymic-derived natural Foxp3+Treg therefore are skewed towards a profile of 
self-recognition and express the transcription factor Foxp3 [43-45].  
Thymic negative selection is not absolute, and autoreactive T cells escape the thymus, 
but are held in check by peripheral tolerance mechanisms. In individuals with T1D and in 
NOD mice, inability of peripheral tolerance regulatory mechanisms to suppress autoreactive 
T cells leads to pathology. 
1.5 Immunoregulatory T cells (Treg) are important for maintaining self-tolerance in the 
periphery 
In T1D β cell antigen priming of naïve CD4+ T cells in the periphery preferentially 
skews towards type 1 or Th1 cell differentiation [20, 46]. In the early 90’s peripheral 
tolerance and progression of T cell-mediated autoimmunity, such as T1D, was viewed as an 
imbalance between pathogenic Th1 cells and protective Th2 cells. However, it is now 
apparent that CD4+ T cells can differentiate into a variety of subsets depending on the 
inflammatory environment, including pathogenic Th17 and various protective Treg subsets. 
Th1 cells produce IFNγ, TNFα, and promote isotype switching of immunoglobulin (Ig) to 
IgG2A [46]. Th17 cells are characterized by production of IL-17, IL-21, IL-22, and GM-CSF 
[47]. Th2 cells on the other hand, produce IL-4, IL-5, IL-13, and aid in antibody production 
[46]. Skewing of naïve CD4+ T cell to a particular Th phenotype depends on T cell-APC 
interaction. IL-12, a cytokine produced by DC and macrophages, promotes robust 
differentiation of a Th1-like response in vitro and in vivo, and concomitantly, has been shown 
to exacerbate T1D in NOD mice [48]. IL-21, produced by Th17 cells, promotes islet 
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infiltration and β cell destruction in NOD mice. This is demonstrated by studies showing that 
lack of IL-21 signaling was sufficient to reduce insulitis and protect NOD mice from disease 
[49, 50].  
Foxp3+Treg attenuate the Th1 and Th17 effector response. Unlike Foxp3+Treg, 
adaptive or induced Treg (iTreg) arise from naïve T cells in the periphery following antigen 
encounter [51]. Naïve CD4+CD25- T cells can differentiate in to IL-10-expressing Tr1 cells 
or TGF-β-expressing Th3 cells that act in concert with Foxp3+Treg to maintain peripheral 
tolerance. Th2 cell cytokines such as IL-4, and Tr1 cells inhibit Th1 cell proliferation and 
protect NOD mice from developing disease [46, 52-54]. Presence of a pro-inflammatory 
milieu in the islets is likely to promote recruitment of autoreactive T cells into the islets and 
exacerbate disease. Thus, maintaining a balance between pro-inflammatory and regulatory 
responses, and determining factors controlling T cell plasticity, is necessary to prevent T1D.  
The importance of Foxp3+Treg in curbing autoimmunity is evident in 
lymphoproliferative disorders (LPDs) in mice and humans with Foxp3 gene defects [45]. 
Mutations in human Foxp3 gene result in immune dysregulation polyendocrinopathy 
enteropathy X-linked syndrome (IPEX), characterized by multi-organ autoimmunity 
including T1D, thyroiditis, and gastritis [55]. Similarly, defects in mouse Foxp3 gene in the 
Scurfy mouse strain results in fatal hyperactivation of T cells [56]. In NOD mice, deletion of 
Foxp3 results in hyperactivtion and proliferation of T cells as well, pointing to a critical role 
for Foxp3+Treg-mediated control of Teff to maintain peripheral tolerance [57]. 
Based on murine studies, human FOXP3+Treg were identified through expression of 
surface CD25 (IL-2Rα chain) and intracellular FoxP3, as a Treg-specific marker. However, 
subsequent studies showed that activated naïve T cells also express high levels of CD25 and 
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FoxP3 in humans, thus confounding the use of FoxP3 as a lone marker for FOXP3+Treg. 
Recent studies have shown that lack of expression of CD127 (IL-7Rα) on CD4+ T cell 
enriches for a suppressive FOXP3+Treg population [58]. Human FOXP3+Treg are therefore 
characterized by high expression of CD25 and FOXP3, and low expression of CD127. 
1.6 Foxp3+Treg-mediated suppression of Teff  
Human and mouse Foxp3+Treg mediate suppression of Teff in a variety of ways, 
including contact-mediated suppression and via cytokine secretion. In addition, the make-up 
of the local inflammatory environment where Foxp3+Treg are present also affects 
Foxp3+Treg suppressive function. Defects in Foxp3+Treg, and factors that render Teff 
resistant to suppression by Foxp3+Treg contribute to development of T1D in mouse and 
human and are discussed herein [59].  
Contact-dependent suppression by Foxp3+Treg relies on upregulation of surface 
molecules such as cytotoxic T lymphocyte antigen 4 (CTLA-4), lymphocyte activating gene 
3 (LAG3), granzyme A, and CD95 (Fas) [60]. Recent studies have shown that LAG3 is 
necessary for optimal Foxp3+Treg suppressor function, although exact mechanisms by how 
LAG3, granzyme A and CD95 mediate Foxp3+Treg suppression in vivo have yet to be 
determined [61, 62]. In addition to CD25, Foxp3+Treg constitutively express CTLA-4. 
CTLA-4 is a negative regulator of T cell activation and interacts with CD80 and CD86 on 
DC. Importantly, mice deficient for CTLA-4 develop spontaneous autoimmune disease and 
Foxp3+Treg derived from CTLA-4-deficient mice show reduced suppression of Teff in vitro 
and in vivo [63, 64]. Notably, mutations in the ctla4 gene are mapped to T1D susceptibility 
loci idd5 and IDDM12 in mouse and humans, respectively [13]. 
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Immunoregulatory cytokines, such as IL-10 and TGF-β, have been the focus of 
numerous studies of Foxp3+Treg suppressor activity. There is clearly a requirement of IL-10 
and TGF-β for development of Tr1 and Th3 cells in vivo. For example, IL-10 and TGF-β 
production by Foxp3+Treg is required for preventing colitis in IBD-prone mice [60, 65]. Of 
interest, a recently discovered immunoregulatory cytokine, IL-35, is expressed by 
Foxp3+Treg and is essential for suppression of pathogenic Teff [66, 67]. IL-35 is a 
heterodimer of Epstein-Barr-virus-induced gene 3 (Ebi3) and interleukin-12 alpha (IL-12α) 
subunits, both of which are expressed in Foxp3+Treg but not in activated Teff [68]. 
Additionally, Ebi3- and IL-12α-deficient Foxp3+Treg are unable to suppress T cell 
proliferation in vitro and in vivo [68]. The role these immunoregulatory cytokines play in 
regulating function and maintenance of Foxp3+Treg in vivo is largely unknown. 
NOD mice exhibit an age-dependent decrease in Foxp3+Treg. Whether islet 
FOXP3+Treg number or function in T1D patients decreases following disease onset has yet 
to be conclusively determined. This is hindered by lack of availability of pancreases from 
T1D patients correlating with various stages of disease. However, a recent study examining 
pancreases of 29 recent-onset diabetics demonstrated that FOXP3+Treg were present in only 
one patient, and even then at very low numbers [19]. Similarly, decreased numbers of islet 
Foxp3+Treg over time correlates with the progression of β cell destruction [69]. 
Studies in NOD mice and in T1D patients have shown that pathogenic Teff are 
relatively resistant to Foxp3+Treg-mediated suppression [70, 71]. In human T1D, resistance 
to FOXP3+Treg suppression is intrinsic to Teff, since neither FOXP3+Treg nor iTreg inhibit 
Teff proliferation in vitro [70]. Interestingly, resistance of Teff to suppression by Foxp3+Treg 
is also observed in animal models for multiple sclerosis and systemic lupus erythematous 
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SLE [59, 70, 72, 73]. Notably, NOD mice can be rescued from T1D through adoptive 
transfer of Foxp3+Treg, as well as by treatment with IL-2, a cytokine critical for Foxp3+Treg 
development, maintenance, and function [69, 74]. 
1.7 IL-35-mediated suppression of autoimmunity 
Cytokine-mediated suppression by Foxp3+Treg relies on secretion of 
immunoregulatory cytokines such as the newly discovered IL-35. IL-35 is an 
immunosuppressive cytokine required for maximal Foxp3+Treg mediated suppression in 
vitro and in vivo [66]. Treatment of naïve T cells with IL-35 results in differentiation of a 
FoxP3- regulatory population, known as Tr35 cells [66]. Tr35 cells are characterized by 
secretion of IL35, but not IL-10 or TGFβ. Mechanistically, IL-35 inhibits T cell proliferation, 
Th1 and Th17 cell differentiation, and has previously been shown to have therapeutic effects 
in various models of T cell-mediated pathology, including IBD and experimental 
autoimmune encephalomyelitis (EAE) [75]. Importantly, generation of transgenic NOD mice 
with β cell-restricted expression of IL-35 results in significantly reduced diabetes incidence 
compared to control wild-type NOD mice [76]. Protection was primarily mediated by 
reduced proliferation of islet resident CD4+ and CD8+ T cells that corresponded to reduced 
frequencies of IFNγ-producing Teff and β-cell antigen-specific T cells [76]. Whether IL-35 
therapy prevents or delays diabetes in recent onset or pre-diabetic NOD mice is unknown and 
is the focus of Chapter 2 in this dissertation.  
IL-35 signals through a heterodimer of IL-12Rβ2 and gp130, although it can also 
alternatively signal through gp130 and IL-12Rβ2 homodimers [77]. While gp130 is 
ubiquitously expressed among T cells, IL-12Rβ2 is primarily expressed by activated T cells 
and is upregulated in response to IL-2 and IL-27, among other cytokines [77-81]. Mutations 
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in the IL-12Rβ2 gene have been linked to development of Crohn’s disease, psoriasis, and 
even T1D [76, 82-84]. IL-35 is unique in that it shares the gp130 subunit with IL-27, leading 
to downstream phosphorylation of STAT1 and STAT4 molecules [77]. Data suggests that 
signaling through both STAT1 and STAT4 molecules is required to mediate IL-35-dependent 
differentiation of T cells into Tr35 cells and that signaling through gp130 or IL-12Rβ2 
homodimers instead limits the suppressive function of IL-35 [77]. 
1.8 Role of IL-2 in T1D etiology  
In addition to reduced Foxp3+Treg numbers, pathogenesis of T1D in NOD mice is 
marked by reduced numbers of NKT cells and impaired costimulation of naïve T cells by 
APCs [20]. Costimulation is necessary not only for conventional T cell activation but also for 
development and maintenance of Foxp3+Treg as alluded to earlier. This is exhibited by the 
reduced Treg pool in CD28-deficient NOD mice, which leads to exacerbated T1D 
development [85, 86]. As discussed above, IL-2 therapy in NOD mice reverses diabetes [87]. 
To better understand the use of IL-2 therapy to protect spontaneous T1D development, it is 
imperative to first discuss Foxp3+Treg dependency upon IL-2.  
IL-2 signals through the IL-2R, which consists of IL-2Rα (CD25), IL-2Rβ (CD122), 
and the common γ chain (γc) (CD132) [51]. CD25, a component of the high-affinity IL-2R, is 
required for Foxp3+Treg development and maintenance in the periphery. Deficiencies in IL-
2, IL-2Rα, or IL-2Rβ in mouse and human lead to fatal LPD and organ-specific 
autoimmunity [88-90]. IL-2 deficiency results in accelerated T1D in NOD mice, 
characterized by reduced number and proliferation of Foxp3+Treg in the thymus and 
periphery [91]. IL-2 administration, on the other hand, induces Foxp3+Treg proliferation and 
upregulates CD25 expression on Foxp3+Treg [51]. Islet-infiltrating Foxp3+Treg in NOD 
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mice display reduced expression of CD25, FoxP3, and the anti-apoptotic molecule Bcl-2, 
suggesting that IL-2 is necessary to maintain and prevent apoptosis of Foxp3+Treg in vivo 
[69]. These defects can be attributed to impaired IL-2 production and IL-2/IL-2R signaling.  
IL-2 is produced by conventional T cells and DC and acts in a paracrine manner to 
maintain the Foxp3+Treg pool. Therefore it has an essential role in maintaining immune 
homeostasis [92]. Administration of low dose IL-2 increases survival and proliferation of 
Foxp3+Treg, whereas higher doses of IL-2 preferentially activate Teff and NK cells [69, 87]. 
This is due to the fact that Foxp3+Treg are highly responsive to IL-2 at lower doses than are 
needed to activate Teff, primarily due to constitutive expression of CD25 by Foxp3+Treg. IL-
2/IL-2R engagement initiates signaling through the Jak/STAT pathway and activation of 
STAT5. These downstream signaling events lead to upregulation of IL-2-dependent genes 
such as Foxp3, which in turn increases CD25 expression that sustains increased IL-2R 
signaling in a feedback loop [93]. Impaired maintenance of Foxp3 expression stemming from 
defects in IL-2R signaling is characterized by reduced phosphorylation of STAT5 and 
increased expression of PTPN2 in T1D patients [94]. Inhibitors of IL-2R signaling, including 
protein tyrosine phosphatases such as PTPN2, are critical in regulating the IL-2R signaling 
cascade. Defects in the IL-2/IL-2R signaling pathway, and polymorphisms in the IL-2, IL-
2Rα, and PTPN2 genes are associated with T1D development in both NOD mice and 
humans [94]. For instance, the IL-2 gene maps to idd3 in NOD mice [95, 96], and NOD mice 
congenic for the C57BL/6-derived idd3 locus are protected from diabetes [97]. 
The central role IL-2 plays in T1D pathogenesis makes it an attractive and promising 
target for immunotherapy. Low dose IL-2 has been used in the clinic for treatment of patients 
with HIV, graft versus host disease (GvHD), and cancer [92]. In cancer, IL-2 therapy is used 
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to selectively expand Teff to prevent suppression of anti-tumor Teff. Advances in preventing 
GvHD have demonstrated a protective role for FOXP3+Treg [98, 99]. GvHD develops when 
donor T cells recognize host MHC antigens and is a concern in both allogeneic and 
mismatched recipients even with the administration of immunosuppressive drugs. Therefore, 
suppressing donor Teff may spare target tissues from destruction. In fact, in mouse studies 
both Foxp3+Treg and induced Treg subsets prevent disease following bone marrow 
transplantation. In addition to low dose IL-2 therapy, targeting the IL-2R signaling pathway 
has also been beneficial in NOD mice [92]. As mentioned above, dosage of IL-2 was 
important in preferentially increasing Foxp3+Treg and preventing disease. However, IL-2 
therapy in humans either alone or in combination with rapamycin, an agonist of mammalian 
target of rapamycin complex (mTORC1), led to increased eosinophilia, NK cell function, and 
exacerbated β cell autoimmunity [100]. These adverse effects on β cell function could be due 
to systemic toxicity associated with the pleiotropic nature of IL-2. 
1.9 Clinical options for T1D treatment and management 
To date, there is no therapy that can prevent T1D. Although risk of T1D development 
increases up to 90% in first-degree relatives of T1D patients, more than 80% of newly 
diagnosed patients do not have any family history of the disease, making it difficult to enroll 
T1D susceptible individuals in prevention trials [1]. Diagnosis of T1D in the clinic is usually 
made on the basis hyperglycemia in conjunction with presence of one or more anti-islet 
autoantibodies, such as for insulin or GAD65 [1]. These diagnostic criteria preclude 
erroneous diagnosis of individuals with insulin-resistant type 2 diabetes (T2D). Once 
diagnosed, administration of daily exogenous insulin is necessary to maintain normal blood 
glucose levels. Alternatively, whole pancreas and islet transplantation have been performed 
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in T1D patients with varying degrees of success, which is measured by a period of insulin 
independence following transplantation. Islet transplantation is hampered by the need for 
multiple donors to achieve adequate number of islets for transplantation. Transplantation 
requires allogeneic donors and a regimen of immunosuppressive agents to prevent rejection 
of the transplanted organ. Life-long use of immunosuppressants to prevent graft rejection and 
to keep autoimmunity in check necessitates better treatments and a cure for T1D. 
1.10 Immunotherapy approaches for T1D 
Antigen-specific therapies involving GAD65 or insulin administration have failed to 
effectively prevent T1D in at risk subjects [101, 102]. On the other hand, non-mitogenic anti-
CD3 antibody (Teplizumab), engineered to prevent binding to Fc receptors, maintained 
residual β cell mass for up to 5 years in some patients, although diabetes reversal was not 
achieved [102-104]. Success of non-mitogenic anti-CD3 antibody in NOD mice was 
characterized by restoring the balance between Teff and Foxp3+Treg via depletion of Teff 
and expansion of Foxp3+Treg [4]. Similar immunotherapy approaches in recent-onset 
diabetic subjects treated with anti-human CD20 antibody (rituximab), or CTLA-4Ig have 
yielded modest success in clinical trials characterized by short-term preservation of inulin 
responses [105, 106].  
In NOD mice, cytokine-mediated immunotherapies have been successful in disease 
prevention. Notably, IL-4 and IL-10 treatment of NOD mice expand Treg and prevent T1D 
development [107, 108]. As stated above, low dose IL-2 therapy expands Foxp3+Treg and 
prevents disease development but not without complications associated with systemic 
administration of IL-2. Success of cytokine based immunotherapy approaches rely on strict 
dosing regimens and continuous administration for long-term treatment. These considerations 
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and the off-target effects associated with systemic cytokine delivery hinder development of 
successful long-term outcomes for T1D treatment in the clinic. As opposed to systemic IL-2 
delivery, targeting IL-2 expression to β cells in NOD mice leads to an islet-specific 
expansion of a qualitatively distinct pool of Foxp3+Treg in NOD mice, which suppresses 
ongoing β cell autoimmunity and prevents diabetes onset in NOD mice [109]. The effect of 
tissue-specific expression of human IL-2 on human FOXP3+Treg however remains unknown 
and is the topic of Chapter 3 of this dissertation.  
To date, the lack of long-term suppression of β cell autoimmunity and/or reversal of 
diabetes further highlights the need for effective immunotherapies in the clinic. Tissue-
specific gene therapy provides a promising approach to restore or preserve islet-function in 
T1D patients. Utilization of adeno-associated virus (AAV) vector-mediated gene therapy 
approach is a safe and robust tool to achieve this goal to treat T1D. 
1.11 Using AAV vectors for immunotherapy  
AAV vectors have become the preferred tools for gene therapy. The initial discovery 
that AAV showed limited pathogenicity in infected humans presented the potential for 
exploiting AAV as a vehicle for gene therapy [110]. Successful infection of AAV in humans 
requires co-infection with a helper virus such as herpes simplex virus (HSV) or adenovirus 
[110, 111]. Thus, despite a large proportion of AAV serotype-positive individuals 
worldwide, AAV infection has not been associated with disease in humans [111]. AAV is a 
parvovirus that consists of a single-stranded (ss) genome 4.7 kilobases (kb) in length. Upon 
injection, ssAAV vector is converted to transcriptionally active double-stranded (ds) DNA, 
which is critical for transgene expression. To circumvent this 'rate-limiting' step, dsAAV 
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vectors have been engineered to permit rapid transgene expression in vivo [112]. Both ss and 
ds AAV vectors are used effectively for gene transfer in vivo.  
One of the major strengths of using AAV vectors is that various cell types can be 
targeted in vivo, depending on the AAV capsid protein employed for packaging [110, 113, 
114]. Up to 13 distinct AAV serotype capsids have been isolated which exhibit tropism for 
particular tissues in the body [110]. Notably, AAV vector serotype 8 shows strong tropism 
and high transduction efficiency for the pancreas [110, 112, 115, 116]. In addition, efforts are 
ongoing to engineer novel capsid proteins using “DNA shuffling’ strategies for instance, to 
enhance tropism for given tissues while limiting immunogenicity [117].  
Additional advantages of AAV vector gene delivery include limited pre-existing 
AAV-specific immunity, establishment of stable long-term transgene expression, and ability 
to transduce both replicating and non-replicating cells [118]. Additionally, safety and 
efficacy of gene therapy using AAV vectors in the clinic has been established [119, 120]. 
AAV vectors have been used to treat a multitude of disorders in the clinic, such as 
hemophilia, cystic fibrosis, Parkinson’s disease, and muscular dystrophy [114, 121-124]. 
AAV vectors have also been utilized to successfully prevent disease in NOD mice as well as 
in STZ-induced model of diabetes [52, 53, 109, 115, 125]. Successful diabetes prevention in 
mouse models have relied on AAV vector serotype 8 capsid for efficient transduction and the 
use of a murine insulin-II promoter (mIP) to specifically target transgene expression to β 
cells in vivo [52, 109, 115]. This approach limits the possibility of systemic transgene 
expression and off-target effects. 
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1.12 Humanized mouse model to study human immune responses 
Failure to translate efficacy induced by immunotherapies in NOD mice to the clinic 
has been a major hurdle within the field. This is attributed to intrinsic differences between the 
human and murine immune systems. Accordingly, there is a need to study the direct effects 
of immunotherapies on human immune effectors in vivo. The latter has led to the 
development and use of “humanized” mice [126-128].  
Immunodeficient mice can be “humanized” via injection of peripheral blood 
mononuclear cells (PBMC), hematopoietic stem cells (HSC) alone, or in conjunction with 
implantation of autologous fetal liver and thymus tissues (BLT) [129, 130]. Early reports 
demonstrating engraftment of human PBMC in immunodeficient NOD.scid mice resulted in 
minimal engraftment of human immune cells, and the need for prohibitively large numbers of 
PBMC [129, 131-134]. Development of NOD.scid (NSG) and NOD.Ragnull  (NRG) mice 
bearing a null mutation of the IL-2R γc allowed for increased engraftment of human PBMC 
and HSC, particularly human T cells [126, 135, 136]. IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 
all signal through γc and the lack of γc in these mice results in severe defects in innate and 
adaptive arms of the immune system [92].  
NRG mice engrafted with human PBMC (hu-PBL-NRG) show robust engraftment of 
T cells but not B cells, NK cells, NK T cells, DC or macrophages [127]. Islet autoantibodies 
can be detected in peripheral blood of hu-PBL-NRG mice injected with PBMC derived from 
T1D donors, but these mice do not demonstrate T cell infiltration of the islets [129]. 
However, a report showed that NSG mice transgenic for human HLA-2.1 expression and 
engrafted with PBMC derived from T1D but not healthy donors exhibited islet-infiltration by 
T cells [137].  
  19 
Humanized mice can also be used to model hyperglycemia. Hyperglycemia in T cell-
engrafted NRG or NSG mice induced chemically by streptozotocin (STZ) is reversed by 
transplantation of human islets [135]. Mouse models of non-immune spontaneous 
hyperglycemia have also been generated [138, 139]. These mice harbor a mutation in the 
mouse insulin 2 gene (Ins2Akita) that results in unstable insulin expression and spontaneous β 
cell apoptosis. Spontaneously diabetic NRG.Ins2Akita mice support engraftment with human 
PBMC, and transplantation of human islets in these mice restores euglycemia [138]. 
The advantages of using mice engrafted with a fully functional human immune 
system, including T cells, should aid in developing more effective clinical therapies. Despite 
the many advantages outlined here, there do exist some limitations that need to be taken into 
account in studies utilizing humanized mice. Hu-PBL-NRG mice, for example, exhibit 
xGvHD 30-40 days following injection of PBMC characterized by pancreatitis and 
infiltration of the liver and skin among other organs, which limits the window of time in 
which experimental studies can be performed [133]. Recently generated NSG mice lacking 
MHC class I and II, NSG. β2mnull and NSG.Abnull, respectively, exhibit significantly delayed 
progression of xGvHD following engraftment, and should help overcome some of these 
limitations [133]. 
1.13 Goals and findings of the dissertation 
The autoimmune response of T1D is marked by infiltration of the pancreatic islets 
with β cell-specific Teff and protective Foxp3+Treg. While it is widely accepted that the 
balance between Foxp3+Treg and Teff is important in determining the risk and kinetics of 
disease development, mechanisms regulating immunoregulatory responses to autoreactive T 
cells in T1D pathogenesis are not completely understood. Foxp3+Treg use a variety of 
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mechanisms to suppress Teff in the periphery, including cytokines that have potent 
immunoregulatory effects. IL-35 is one such cytokine secreted by Foxp3+Treg that inhibits T 
cell activation, proliferation, and promotes Tr35 differentiation. A recent study demonstrated 
that transgenic NOD mice expressing β cell-specific IL-35 exhibit reduced incidence of T1D 
due, in part, to a reduction in pathogenic CD4+ and CD8+ Teff in the islets. The 
immunotherapeutic potential of IL-35, however, is ill-defined. In the first part of our studies, 
we examined the therapeutic potential of IL-35 in NOD female mice at a late preclinical 
stage of T1D. NOD mice vaccinated with AAV serotype 8 vector packaged with mIP-driven 
IL-35 (AAV8mIP-IL35) exhibited reduced islet CD4+ and CD8+ T cells numbers, which 
corresponded with reduced islet T cell proliferation and islet-resident DC numbers. 
Furthermore, ectopic IL-35 expression led to a qualitatively distinct pool of Teff and 
Foxp3+Treg. Islet CD4+ T cells exhibited reduced expression of IFNg+ and islet Foxp3+Treg 
displayed high levels of CTLA-4. The effects of ectopic IL-35 were islet-specific since the 
frequency, number and activation status of splenic T cells were unchanged in AAVmIP-IL35 
treated animals. Islet-restricted IL-35 expression effectively blocked progression to overt 
diabetes in the majority of NOD mice. Together, these findings demonstrate that islet-
restricted IL-35 expression is sufficient to suppress ongoing β cell autoimmunity and that 
immunotherapy using IL-35 is a promising approach to treat T1D as well as other T cell-
mediated pathologies.  
Not unlike murine Foxp3+Treg, human FOXP3+Treg are potent mediators of 
peripheral tolerance. IL-2R signaling is crucial for maintaining the Foxp3+Treg pool. Studies 
using NOD mice have shown that reduced IL-2 levels result in diminished survival of islet 
Foxp3+Treg leading to expansion of pathogenic Teff. Notably, in vitro studies have 
  21 
demonstrated that FOXP3+Treg from T1D patients exhibit impaired responsiveness to IL-2 
thereby reducing survival and function. Furthermore, defects in the IL-2R signaling pathway 
have been implicated in conferring susceptibility to T1D in humans. In the second part of our 
studies, we investigated the effects of ectopic IL-2 expression on human FOXP3+Treg. We 
utilized hu-PBL-NRG “humanized” mice to determine the response of T1D and non-T1D 
derived FOXP3+Treg to AAV8mIP-hIL2 immunotherapy in vivo. AAV8mIP-hIL2 treatment 
expanded non-T1D and T1D-derived pancreatic FOXP3+Treg in hu-PBL-NRG mice. These 
early findings indicate a promising approach to study the effect of IL-2 on human 
FOXP3+Treg phenotype and suppressive function in vivo.  
  22 
1.14 REFERENCES 
1 Atkinson, M. A. and Eisenbarth, G. S., Type 1 diabetes: new perspectives on 
disease pathogenesis and treatment. Lancet 2001. 358: 221-229. 
2 Onkamo, P., Vaananen, S., Karvonen, M. and Tuomilehto, J., Worldwide 
increase in incidence of Type I diabetes--the analysis of the data on published 
incidence trends. Diabetologia 1999. 42: 1395-1403. 
3 van Belle, T. L., Coppieters, K. T. and von Herrath, M. G., Type 1 diabetes: 
etiology, immunology, and therapeutic strategies. Physiol Rev 2011. 91: 79-118. 
4 Bluestone, J. A., Herold, K. and Eisenbarth, G., Genetics, pathogenesis and 
clinical interventions in type 1 diabetes. Nature 2010. 464: 1293-1300. 
5 Kent, S. C., Chen, Y., Bregoli, L., Clemmings, S. M., Kenyon, N. S., Ricordi, C., 
Hering, B. J. and Hafler, D. A., Expanded T cells from pancreatic lymph nodes of 
type 1 diabetic subjects recognize an insulin epitope. Nature 2005. 435: 224-228. 
6 Nakayama, M., Abiru, N., Moriyama, H., Babaya, N., Liu, E., Miao, D., Yu, L., 
Wegmann, D. R., Hutton, J. C., Elliott, J. F. and Eisenbarth, G. S., Prime role for 
an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005. 
435: 220-223. 
7 Wucherpfennig, K. W. and Eisenbarth, G. S., Type 1 diabetes. Nat Immunol 2001. 
2: 767-768. 
8 Davies, J. L., Kawaguchi, Y., Bennett, S. T., Copeman, J. B., Cordell, H. J., 
Pritchard, L. E., Reed, P. W., Gough, S. C., Jenkins, S. C., Palmer, S. M. and et 
al., A genome-wide search for human type 1 diabetes susceptibility genes. Nature 
1994. 371: 130-136. 
9 Lohmann, T., Leslie, R. D. and Londei, M., T cell clones to epitopes of glutamic 
acid decarboxylase 65 raised from normal subjects and patients with insulin-
dependent diabetes. J Autoimmun 1996. 9: 385-389. 
10 Concannon, P., Rich, S. S. and Nepom, G. T., Genetics of type 1A diabetes. N Engl 
J Med 2009. 360: 1646-1654. 
11 Castano, L. and Eisenbarth, G. S., Type-I diabetes: a chronic autoimmune disease 
of human, mouse, and rat. Annu Rev Immunol 1990. 8: 647-679. 
12 Tisch, R. and McDevitt, H., Insulin-dependent diabetes mellitus. Cell 1996. 85: 291-
297. 
13 Maier, L. M. and Wicker, L. S., Genetic susceptibility to type 1 diabetes. Curr Opin 
Immunol 2005. 17: 601-608. 
  23 
14 Atkinson, M. A., Eisenbarth, G. S. and Michels, A. W., Type 1 diabetes. Lancet 
2014. 383: 69-82. 
15 Coppieters, K. T., Boettler, T. and von Herrath, M., Virus infections in type 1 
diabetes. Cold Spring Harb Perspect Med 2012. 2: a007682. 
16 Serreze, D. V., Ottendorfer, E. W., Ellis, T. M., Gauntt, C. J. and Atkinson, M. 
A., Acceleration of type 1 diabetes by a coxsackievirus infection requires a 
preexisting critical mass of autoreactive T-cells in pancreatic islets. Diabetes 2000. 
49: 708-711. 
17 Qin, H. Y. and Singh, B., BCG vaccination prevents insulin-dependent diabetes 
mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J 
Autoimmun 1997. 10: 271-278. 
18 Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., 
Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., Gordon, J. 
I. and Chervonsky, A. V., Innate immunity and intestinal microbiota in the 
development of Type 1 diabetes. Nature 2008. 455: 1109-1113. 
19 Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K. and Morgan, N. G., 
Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009. 
155: 173-181. 
20 Anderson, M. S. and Bluestone, J. A., The NOD mouse: a model of immune 
dysregulation. Annu Rev Immunol 2005. 23: 447-485. 
21 Serreze, D. V., Fleming, S. A., Chapman, H. D., Richard, S. D., Leiter, E. H. and 
Tisch, R. M., B lymphocytes are critical antigen-presenting cells for the initiation of 
T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 1998. 
161: 3912-3918. 
22 Turley, S., Poirot, L., Hattori, M., Benoist, C. and Mathis, D., Physiological beta 
cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 
diabetes model. J Exp Med 2003. 198: 1527-1537. 
23 Campbell, I. L., Iscaro, A. and Harrison, L. C., IFN-gamma and tumor necrosis 
factor-alpha. Cytotoxicity to murine islets of Langerhans. J Immunol 1988. 141: 
2325-2329. 
24 Suk, K., Kim, S., Kim, Y. H., Kim, K. A., Chang, I., Yagita, H., Shong, M. and 
Lee, M. S., IFN-gamma/TNF-alpha synergism as the final effector in autoimmune 
diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta 
cell death. J Immunol 2001. 166: 4481-4489. 
25 Graham, K. L., Sutherland, R. M., Mannering, S. I., Zhao, Y., Chee, J., 
Krishnamurthy, B., Thomas, H. E., Lew, A. M. and Kay, T. W., Pathogenic 
  24 
mechanisms in type 1 diabetes: the islet is both target and driver of disease. Rev 
Diabet Stud 2012. 9: 148-168. 
26 Hamilton-Williams, E. E., Palmer, S. E., Charlton, B. and Slattery, R. M., Beta 
cell MHC class I is a late requirement for diabetes. Proc Natl Acad Sci U S A 2003. 
100: 6688-6693. 
27 Katz, J., Benoist, C. and Mathis, D., Major histocompatibility complex class I 
molecules are required for the development of insulitis in non-obese diabetic mice. 
Eur J Immunol 1993. 23: 3358-3360. 
28 Wong, F. S., Visintin, I., Wen, L., Flavell, R. A. and Janeway, C. A., Jr., CD8 T 
cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of 
diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996. 183: 67-76. 
29 Christianson, S. W., Shultz, L. D. and Leiter, E. H., Adoptive transfer of diabetes 
into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and 
CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 
1993. 42: 44-55. 
30 Mora, C., Wong, F. S., Chang, C. H. and Flavell, R. A., Pancreatic infiltration but 
not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: 
studies using NOD/CIITA-deficient mice. J Immunol 1999. 162: 4576-4588. 
31 Germain, R. N., T-cell development and the CD4-CD8 lineage decision. Nat Rev 
Immunol 2002. 2: 309-322. 
32 von Boehmer, H. and Fehling, H. J., Structure and function of the pre-T cell 
receptor. Annu Rev Immunol 1997. 15: 433-452. 
33 Klein, L., Kyewski, B., Allen, P. M. and Hogquist, K. A., Positive and negative 
selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev 
Immunol 2014. 14: 377-391. 
34 Klein, L., Hinterberger, M., Wirnsberger, G. and Kyewski, B., Antigen 
presentation in the thymus for positive selection and central tolerance induction. Nat 
Rev Immunol 2009. 9: 833-844. 
35 Gabler, J., Arnold, J. and Kyewski, B., Promiscuous gene expression and the 
developmental dynamics of medullary thymic epithelial cells. Eur J Immunol 2007. 
37: 3363-3372. 
36 Anderson, M. S., Venanzi, E. S., Klein, L., Chen, Z., Berzins, S. P., Turley, S. J., 
von Boehmer, H., Bronson, R., Dierich, A., Benoist, C. and Mathis, D., Projection 
of an immunological self shadow within the thymus by the aire protein. Science 2002. 
298: 1395-1401. 
  25 
37 Li, J., Park, J., Foss, D. and Goldschneider, I., Thymus-homing peripheral 
dendritic cells constitute two of the three major subsets of dendritic cells in the 
steady-state thymus. J Exp Med 2009. 206: 607-622. 
38 Kanagawa, O., Martin, S. M., Vaupel, B. A., Carrasco-Marin, E. and Unanue, E. 
R., Autoreactivity of T cells from nonobese diabetic mice: an I-Ag7-dependent 
reaction. Proc Natl Acad Sci U S A 1998. 95: 1721-1724. 
39 Kishimoto, H. and Sprent, J., A defect in central tolerance in NOD mice. Nat 
Immunol 2001. 2: 1025-1031. 
40 Liston, A., Lesage, S., Gray, D. H., O'Reilly, L. A., Strasser, A., Fahrer, A. M., 
Boyd, R. L., Wilson, J., Baxter, A. G., Gallo, E. M., Crabtree, G. R., Peng, K., 
Wilson, S. R. and Goodnow, C. C., Generalized resistance to thymic deletion in the 
NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity 
2004. 21: 817-830. 
41 Villunger, A., Marsden, V. S. and Strasser, A., Efficient T cell receptor-mediated 
apoptosis in nonobese diabetic mouse thymocytes. Nat Immunol 2003. 4: 717; author 
reply 718. 
42 Wirnsberger, G., Mair, F. and Klein, L., Regulatory T cell differentiation of 
thymocytes does not require a dedicated antigen-presenting cell but is under T cell-
intrinsic developmental control. Proc Natl Acad Sci U S A 2009. 106: 10278-10283. 
43 Fontenot, J. D., Gavin, M. A. and Rudensky, A. Y., Foxp3 programs the 
development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003. 4: 
330-336. 
44 Hori, S., Nomura, T. and Sakaguchi, S., Control of regulatory T cell development 
by the transcription factor Foxp3. Science 2003. 299: 1057-1061. 
45 Khattri, R., Cox, T., Yasayko, S. A. and Ramsdell, F., An essential role for Scurfin 
in CD4+CD25+ T regulatory cells. Nat Immunol 2003. 4: 337-342. 
46 Liblau, R. S., Singer, S. M. and McDevitt, H. O., Th1 and Th2 CD4+ T cells in the 
pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995. 16: 34-
38. 
47 Li, Y., Liu, Y. and Chu, C. Q., Th17 Cells in Type 1 Diabetes: Role in the 
Pathogenesis and Regulation by Gut Microbiome. Mediators Inflamm 2015. 2015: 
638470. 
48 Trembleau, S., Penna, G., Bosi, E., Mortara, A., Gately, M. K. and Adorini, L., 
Interleukin 12 administration induces T helper type 1 cells and accelerates 
autoimmune diabetes in NOD mice. J Exp Med 1995. 181: 817-821. 
  26 
49 Spolski, R., Kashyap, M., Robinson, C., Yu, Z. and Leonard, W. J., IL-21 
signaling is critical for the development of type I diabetes in the NOD mouse. Proc 
Natl Acad Sci U S A 2008. 105: 14028-14033. 
50 Sutherland, A. P., Van Belle, T., Wurster, A. L., Suto, A., Michaud, M., Zhang, 
D., Grusby, M. J. and von Herrath, M., Interleukin-21 is required for the 
development of type 1 diabetes in NOD mice. Diabetes 2009. 58: 1144-1155. 
51 Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z., Shimizu, 
J., Takahashi, T. and Nomura, T., Foxp3+ CD25+ CD4+ natural regulatory T cells 
in dominant self-tolerance and autoimmune disease. Immunol Rev 2006. 212: 8-27. 
52 Rehman, K. K., Trucco, M., Wang, Z., Xiao, X. and Robbins, P. D., AAV8-
mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of 
diabetes in NOD mice. Mol Ther 2008. 16: 1409-1416. 
53 Yang, Z., Chen, M., Wu, R., Fialkow, L. B., Bromberg, J. S., McDuffie, M., Naji, 
A. and Nadler, J. L., Suppression of autoimmune diabetes by viral IL-10 gene 
transfer. J Immunol 2002. 168: 6479-6485. 
54 Mueller, R., Krahl, T. and Sarvetnick, N., Pancreatic expression of interleukin-4 
abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp 
Med 1996. 184: 1093-1099. 
55 Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., 
Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F. and Ochs, H. D., The 
immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) 
is caused by mutations of FOXP3. Nat Genet 2001. 27: 20-21. 
56 Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., 
Yasayko, S. A., Wilkinson, J. E., Galas, D., Ziegler, S. F. and Ramsdell, F., 
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal 
lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001. 27: 68-73. 
57 Chen, Z., Benoist, C. and Mathis, D., How defects in central tolerance impinge on a 
deficiency in regulatory T cells. Proc Natl Acad Sci U S A 2005. 102: 14735-14740. 
58 Liu, W., Putnam, A. L., Xu-Yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. 
A., Kapranov, P., Gingeras, T. R., Fazekas de St Groth, B., Clayberger, C., 
Soper, D. M., Ziegler, S. F. and Bluestone, J. A., CD127 expression inversely 
correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp 
Med 2006. 203: 1701-1711. 
59 Buckner, J. H., Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) 
regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010. 10: 849-
859. 
  27 
60 Vignali, D. A., Collison, L. W. and Workman, C. J., How regulatory T cells work. 
Nat Rev Immunol 2008. 8: 523-532. 
61 Do, J. S., Visperas, A., Sanogo, Y. O., Bechtel, J. J., Dvorina, N., Kim, S., Jang, 
E., Stohlman, S. A., Shen, B., Fairchild, R. L., Baldwin Iii, W. M., Vignali, D. A. 
and Min, B., An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive 
function and therapeutic efficacy. Mucosal Immunol 2016. 9: 137-145. 
62 Huang, C. T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., 
Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., Powell, J. D., Pardoll, D. 
M., Drake, C. G. and Vignali, D. A., Role of LAG-3 in regulatory T cells. Immunity 
2004. 21: 503-513. 
63 Oderup, C., Cederbom, L., Makowska, A., Cilio, C. M. and Ivars, F., Cytotoxic T 
lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on 
dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology 
2006. 118: 240-249. 
64 Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A. and 
Sharpe, A. H., Loss of CTLA-4 leads to massive lymphoproliferation and fatal 
multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. 
Immunity 1995. 3: 541-547. 
65 Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L. and Powrie, F., An 
essential role for interleukin 10 in the function of regulatory T cells that inhibit 
intestinal inflammation. J Exp Med 1999. 190: 995-1004. 
66 Collison, L. W., Chaturvedi, V., Henderson, A. L., Giacomin, P. R., Guy, C., 
Bankoti, J., Finkelstein, D., Forbes, K., Workman, C. J., Brown, S. A., Rehg, J. 
E., Jones, M. L., Ni, H. T., Artis, D., Turk, M. J. and Vignali, D. A., IL-35-
mediated induction of a potent regulatory T cell population. Nat Immunol 2010. 11: 
1093-1101. 
67 Collison, L. W., Pillai, M. R., Chaturvedi, V. and Vignali, D. A., Regulatory T cell 
suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-
dependent manner. J Immunol 2009. 182: 6121-6128. 
68 Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., 
Cross, R., Sehy, D., Blumberg, R. S. and Vignali, D. A., The inhibitory cytokine 
IL-35 contributes to regulatory T-cell function. Nature 2007. 450: 566-569. 
69 Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., 
Piccirillo, C. A., Salomon, B. L. and Bluestone, J. A., Central role of defective 
interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 
2008. 28: 687-697. 
  28 
70 Schneider, A., Rieck, M., Sanda, S., Pihoker, C., Greenbaum, C. and Buckner, J. 
H., The effector T cells of diabetic subjects are resistant to regulation via CD4+ 
FOXP3+ regulatory T cells. J Immunol 2008. 181: 7350-7355. 
71 D'Alise, A. M., Auyeung, V., Feuerer, M., Nishio, J., Fontenot, J., Benoist, C. and 
Mathis, D., The defect in T-cell regulation in NOD mice is an effect on the T-cell 
effectors. Proc Natl Acad Sci U S A 2008. 105: 19857-19862. 
72 Gregori, S., Giarratana, N., Smiroldo, S. and Adorini, L., Dynamics of pathogenic 
and suppressor T cells in autoimmune diabetes development. J Immunol 2003. 171: 
4040-4047. 
73 Monk, C. R., Spachidou, M., Rovis, F., Leung, E., Botto, M., Lechler, R. I. and 
Garden, O. A., MRL/Mp CD4+,CD25- T cells show reduced sensitivity to 
suppression by CD4+,CD25+ regulatory T cells in vitro: a novel defect of T cell 
regulation in systemic lupus erythematosus. Arthritis Rheum 2005. 52: 1180-1184. 
74 Tang, Q., Henriksen, K. J., Bi, M., Finger, E. B., Szot, G., Ye, J., Masteller, E. L., 
McDevitt, H., Bonyhadi, M. and Bluestone, J. A., In vitro-expanded antigen-
specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004. 199: 
1455-1465. 
75 Choi, J., Leung, P. S., Bowlus, C. and Gershwin, M. E., IL-35 and Autoimmunity: 
a Comprehensive Perspective. Clin Rev Allergy Immunol 2015. 
76 Bettini, M., Castellaw, A. H., Lennon, G. P., Burton, A. R. and Vignali, D. A., 
Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of 
interleukin-35. Diabetes 2012. 61: 1519-1526. 
77 Collison, L. W., Delgoffe, G. M., Guy, C. S., Vignali, K. M., Chaturvedi, V., 
Fairweather, D., Satoskar, A. R., Garcia, K. C., Hunter, C. A., Drake, C. G., 
Murray, P. J. and Vignali, D. A., The composition and signaling of the IL-35 
receptor are unconventional. Nat Immunol 2012. 13: 290-299. 
78 Betz, U. A. and Muller, W., Regulated expression of gp130 and IL-6 receptor alpha 
chain in T cell maturation and activation. Int Immunol 1998. 10: 1175-1184. 
79 Hibbert, L., Pflanz, S., De Waal Malefyt, R. and Kastelein, R. A., IL-27 and IFN-
alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J 
Interferon Cytokine Res 2003. 23: 513-522. 
80 Liao, W., Lin, J. X., Wang, L., Li, P. and Leonard, W. J., Modulation of cytokine 
receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat 
Immunol 2011. 12: 551-559. 
81 Presky, D. H., Yang, H., Minetti, L. J., Chua, A. O., Nabavi, N., Wu, C. Y., 
Gately, M. K. and Gubler, U., A functional interleukin 12 receptor complex is 
  29 
composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A 
1996. 93: 14002-14007. 
82 Bossini-Castillo, L., Martin, J. E., Broen, J., Gorlova, O., Simeon, C. P., Beretta, 
L., Vonk, M. C., Callejas, J. L., Castellvi, I., Carreira, P., Garcia-Hernandez, F. 
J., Fernandez Castro, M., Spanish Scleroderma, G., Coenen, M. J., Riemekasten, 
G., Witte, T., Hunzelmann, N., Kreuter, A., Distler, J. H., Koeleman, B. P., 
Voskuyl, A. E., Schuerwegh, A. J., Palm, O., Hesselstrand, R., Nordin, A., Airo, 
P., Lunardi, C., Scorza, R., Shiels, P., van Laar, J. M., Herrick, A., Worthington, 
J., Denton, C., Tan, F. K., Arnett, F. C., Agarwal, S. K., Assassi, S., Fonseca, C., 
Mayes, M. D., Radstake, T. R. and Martin, J., A GWAS follow-up study reveals 
the association of the IL12RB2 gene with systemic sclerosis in Caucasian 
populations. Hum Mol Genet 2012. 21: 926-933. 
83 Cargill, M., Schrodi, S. J., Chang, M., Garcia, V. E., Brandon, R., Callis, K. P., 
Matsunami, N., Ardlie, K. G., Civello, D., Catanese, J. J., Leong, D. U., Panko, J. 
M., McAllister, L. B., Hansen, C. B., Papenfuss, J., Prescott, S. M., White, T. J., 
Leppert, M. F., Krueger, G. G. and Begovich, A. B., A large-scale genetic 
association study confirms IL12B and leads to the identification of IL23R as 
psoriasis-risk genes. Am J Hum Genet 2007. 80: 273-290. 
84 McGovern, D. P., Rotter, J. I., Mei, L., Haritunians, T., Landers, C., Derkowski, 
C., Dutridge, D., Dubinsky, M., Ippoliti, A., Vasiliauskas, E., Mengesha, E., 
King, L., Pressman, S., Targan, S. R. and Taylor, K. D., Genetic epistasis of 
IL23/IL17 pathway genes in Crohn's disease. Inflamm Bowel Dis 2009. 15: 883-889. 
85 Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. and 
Bluestone, J. A., B7/CD28 costimulation is essential for the homeostasis of the 
CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 
2000. 12: 431-440. 
86 Tang, Q., Henriksen, K. J., Boden, E. K., Tooley, A. J., Ye, J., Subudhi, S. K., 
Zheng, X. X., Strom, T. B. and Bluestone, J. A., Cutting edge: CD28 controls 
peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003. 171: 
3348-3352. 
87 Grinberg-Bleyer, Y., Baeyens, A., You, S., Elhage, R., Fourcade, G., Gregoire, 
S., Cagnard, N., Carpentier, W., Tang, Q., Bluestone, J., Chatenoud, L., 
Klatzmann, D., Salomon, B. L. and Piaggio, E., IL-2 reverses established type 1 
diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 
2010. 207: 1871-1878. 
88 Horak, I., Lohler, J., Ma, A. and Smith, K. A., Interleukin-2 deficient mice: a new 
model to study autoimmunity and self-tolerance. Immunol Rev 1995. 148: 35-44. 
89 Sharfe, N., Dadi, H. K., Shahar, M. and Roifman, C. M., Human immune disorder 
arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad 
Sci U S A 1997. 94: 3168-3171. 
  30 
90 Willerford, D. M., Chen, J., Ferry, J. A., Davidson, L., Ma, A. and Alt, F. W., 
Interleukin-2 receptor alpha chain regulates the size and content of the peripheral 
lymphoid compartment. Immunity 1995. 3: 521-530. 
91 Setoguchi, R., Hori, S., Takahashi, T. and Sakaguchi, S., Homeostatic 
maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin 
(IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005. 
201: 723-735. 
92 Hulme, M. A., Wasserfall, C. H., Atkinson, M. A. and Brusko, T. M., Central role 
for interleukin-2 in type 1 diabetes. Diabetes 2012. 61: 14-22. 
93 Dendrou, C. A. and Wicker, L. S., The IL-2/CD25 pathway determines 
susceptibility to T1D in humans and NOD mice. J Clin Immunol 2008. 28: 685-696. 
94 Long, S. A., Cerosaletti, K., Bollyky, P. L., Tatum, M., Shilling, H., Zhang, S., 
Zhang, Z. Y., Pihoker, C., Sanda, S., Greenbaum, C. and Buckner, J. H., Defects 
in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in 
CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010. 59: 
407-415. 
95 Vella, A., Cooper, J. D., Lowe, C. E., Walker, N., Nutland, S., Widmer, B., Jones, 
R., Ring, S. M., McArdle, W., Pembrey, M. E., Strachan, D. P., Dunger, D. B., 
Twells, R. C., Clayton, D. G. and Todd, J. A., Localization of a type 1 diabetes 
locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am 
J Hum Genet 2005. 76: 773-779. 
96 Wicker, L. S., Todd, J. A., Prins, J. B., Podolin, P. L., Renjilian, R. J. and 
Peterson, L. B., Resistance alleles at two non-major histocompatibility complex-
linked insulin-dependent diabetes loci on chromosome 3, Idd3 and Idd10, protect 
nonobese diabetic mice from diabetes. J Exp Med 1994. 180: 1705-1713. 
97 Goudy, K. S., Johnson, M. C., Garland, A., Li, C., Samulski, R. J., Wang, B. and 
Tisch, R., Reduced IL-2 expression in NOD mice leads to a temporal increase in 
CD62Llo FoxP3+ CD4+ T cells with limited suppressor activity. Eur J Immunol 
2011. 41: 1480-1490. 
98 Cohen, J. L., Trenado, A., Vasey, D., Klatzmann, D. and Salomon, B. L., 
CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host 
disease. J Exp Med 2002. 196: 401-406. 
99 Di Ianni, M., Falzetti, F., Carotti, A., Terenzi, A., Castellino, F., Bonifacio, E., 
Del Papa, B., Zei, T., Ostini, R. I., Cecchini, D., Aloisi, T., Perruccio, K., Ruggeri, 
L., Balucani, C., Pierini, A., Sportoletti, P., Aristei, C., Falini, B., Reisner, Y., 
Velardi, A., Aversa, F. and Martelli, M. F., Tregs prevent GVHD and promote 
immune reconstitution in HLA-haploidentical transplantation. Blood 2011. 117: 
3921-3928. 
  31 
100 Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., 
Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., Turka, L. A., Ehlers, 
M. R., Bianchine, P. J., Boyle, K. D., Adah, S. A., Bluestone, J. A., Buckner, J. 
H., Greenbaum, C. J., Diabetes, T. and the Immune Tolerance, N., 
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs 
yet transiently impairs beta-cell function. Diabetes 2012. 61: 2340-2348. 
101 The Diabetes Prevention Trial-Type 1 diabetes (DPT-1): implementation of screening 
and staging of relatives. DPT-1 Study Group. Transplant Proc 1995. 27: 3377. 
102 Jeker, L. T., Bour-Jordan, H. and Bluestone, J. A., Breakdown in peripheral 
tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med 
2012. 2: a007807. 
103 Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, 
L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., Schandene, L., 
Crenier, L., De Block, C., Seigneurin, J. M., De Pauw, P., Pierard, D., Weets, I., 
Rebello, P., Bird, P., Berrie, E., Frewin, M., Waldmann, H., Bach, J. F., 
Pipeleers, D. and Chatenoud, L., Insulin needs after CD3-antibody therapy in new-
onset type 1 diabetes. N Engl J Med 2005. 352: 2598-2608. 
104 Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., 
Jr., Bode, B., Aronoff, S., Holland, C., Carlin, D., King, K. L., Wilder, R. L., 
Pillemer, S., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Herold, K. C., 
Daifotis, A. G. and Protege Trial, I., Teplizumab for treatment of type 1 diabetes 
(Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 
2011. 378: 487-497. 
105 Ludvigsson, J., Faresjo, M., Hjorth, M., Axelsson, S., Cheramy, M., Pihl, M., 
Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., Lindh, A., Nilsson, N. 
O., Aman, J., Ortqvist, E., Zerhouni, P. and Casas, R., GAD treatment and insulin 
secretion in recent-onset type 1 diabetes. N Engl J Med 2008. 359: 1909-1920. 
106 Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., 
Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, 
A. M., Raskin, P., Rodriguez, H., Schatz, D. A., Wherrett, D., Wilson, D. M., 
Lachin, J. M., Skyler, J. S. and Type 1 Diabetes TrialNet Anti, C. D. S. G., 
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J 
Med 2009. 361: 2143-2152. 
107 Pennline, K. J., Roque-Gaffney, E. and Monahan, M., Recombinant human IL-10 
prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol 
Immunopathol 1994. 71: 169-175. 
108 Rapoport, M. J., Jaramillo, A., Zipris, D., Lazarus, A. H., Serreze, D. V., Leiter, 
E. H., Cyopick, P., Danska, J. S. and Delovitch, T. L., Interleukin 4 reverses T cell 
proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic 
mice. J Exp Med 1993. 178: 87-99. 
  32 
109 Johnson, M. C., Garland, A. L., Nicolson, S. C., Li, C., Samulski, R. J., Wang, B. 
and Tisch, R., beta-cell-specific IL-2 therapy increases islet Foxp3+Treg and 
suppresses type 1 diabetes in NOD mice. Diabetes 2013. 62: 3775-3784. 
110 Wu, Z., Asokan, A. and Samulski, R. J., Adeno-associated virus serotypes: vector 
toolkit for human gene therapy. Mol Ther 2006. 14: 316-327. 
111 Smith, R. H., Adeno-associated virus integration: virus versus vector. Gene Ther 
2008. 15: 817-822. 
112 Wang, Z., Ma, H. I., Li, J., Sun, L., Zhang, J. and Xiao, X., Rapid and highly 
efficient transduction by double-stranded adeno-associated virus vectors in vitro and 
in vivo. Gene Ther 2003. 10: 2105-2111. 
113 Asokan, A., Schaffer, D. V. and Samulski, R. J., The AAV vector toolkit: poised at 
the clinical crossroads. Mol Ther 2012. 20: 699-708. 
114 Mingozzi, F. and High, K. A., Therapeutic in vivo gene transfer for genetic disease 
using AAV: progress and challenges. Nat Rev Genet 2011. 12: 341-355. 
115 Riedel, M. J., Gaddy, D. F., Asadi, A., Robbins, P. D. and Kieffer, T. J., 
DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells 
ameliorates streptozotocin-induced diabetes. Gene Ther 2010. 17: 171-180. 
116 Wang, A. Y., Peng, P. D., Ehrhardt, A., Storm, T. A. and Kay, M. A., Comparison 
of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. 
Hum Gene Ther 2004. 15: 405-413. 
117 Tseng, Y. S. and Agbandje-McKenna, M., Mapping the AAV Capsid Host 
Antibody Response toward the Development of Second Generation Gene Delivery 
Vectors. Front Immunol 2014. 5: 9. 
118 Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. 
T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., Spencer, C., Byrne, B. 
J., Wilson, J. M. and Flotte, T. R., Sustained transgene expression despite T 
lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad 
Sci U S A 2009. 106: 16363-16368. 
119 Rabinowitz, J. E. and Samulski, J., Adeno-associated virus expression systems for 
gene transfer. Curr Opin Biotechnol 1998. 9: 470-475. 
120 Terzi, D. and Zachariou, V., Adeno-associated virus-mediated gene delivery 
approaches for the treatment of CNS disorders. Biotechnol J 2008. 3: 1555-1563. 
121 Mandel, R. J. and Burger, C., Clinical trials in neurological disorders using AAV 
vectors: promises and challenges. Curr Opin Mol Ther 2004. 6: 482-490. 
  33 
122 Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, 
V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., Couto, L. B., Leonard, 
D. G., Johnson, F. A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A. W., 
Kay, M. A., High, K. A. and Glader, B., AAV-mediated factor IX gene transfer to 
skeletal muscle in patients with severe hemophilia B. Blood 2003. 101: 2963-2972. 
123 Grieger, J. C. and Samulski, R. J., Adeno-associated virus vectorology, 
manufacturing, and clinical applications. Methods Enzymol 2012. 507: 229-254. 
124 Matrai, J., Chuah, M. K. and VandenDriessche, T., Preclinical and clinical 
progress in hemophilia gene therapy. Curr Opin Hematol 2010. 17: 387-392. 
125 Goudy, K., Song, S., Wasserfall, C., Zhang, Y. C., Kapturczak, M., Muir, A., 
Powers, M., Scott-Jorgensen, M., Campbell-Thompson, M., Crawford, J. M., 
Ellis, T. M., Flotte, T. R. and Atkinson, M. A., Adeno-associated virus vector-
mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad 
Sci U S A 2001. 98: 13913-13918. 
126 Brehm, M. A., Cuthbert, A., Yang, C., Miller, D. M., DiIorio, P., Laning, J., 
Burzenski, L., Gott, B., Foreman, O., Kavirayani, A., Herlihy, M., Rossini, A. A., 
Shultz, L. D. and Greiner, D. L., Parameters for establishing humanized mouse 
models to study human immunity: analysis of human hematopoietic stem cell 
engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) 
mutation. Clin Immunol 2010. 135: 84-98. 
127 Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V. and Greiner, D. L., 
Humanized mice for immune system investigation: progress, promise and challenges. 
Nat Rev Immunol 2012. 12: 786-798. 
128 Shultz, L. D., Ishikawa, F. and Greiner, D. L., Humanized mice in translational 
biomedical research. Nat Rev Immunol 2007. 7: 118-130. 
129 Brehm, M. A., Powers, A. C., Shultz, L. D. and Greiner, D. L., Advancing animal 
models of human type 1 diabetes by engraftment of functional human tissues in 
immunodeficient mice. Cold Spring Harb Perspect Med 2012. 2: a007757. 
130 Pearson, T., Greiner, D. L. and Shultz, L. D., Creation of "humanized" mice to 
study human immunity. Curr Protoc Immunol 2008. Chapter 15: Unit 15 21. 
131 Ji, M., Jin, X., Phillips, P. and Yi, S., A humanized mouse model to study human 
immune response in xenotransplantation. Hepatobiliary Pancreat Dis Int 2012. 11: 
494-498. 
132 Pino, S., Brehm, M. A., Covassin-Barberis, L., King, M., Gott, B., Chase, T. H., 
Wagner, J., Burzenski, L., Foreman, O., Greiner, D. L. and Shultz, L. D., 
Development of novel major histocompatibility complex class I and class II-deficient 
NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic 
graft-versus-host disease. Methods Mol Biol 2010. 602: 105-117. 
  34 
133 Shultz, L. D., Pearson, T., King, M., Giassi, L., Carney, L., Gott, B., Lyons, B., 
Rossini, A. A. and Greiner, D. L., Humanized NOD/LtSz-scid IL2 receptor 
common gamma chain knockout mice in diabetes research. Ann N Y Acad Sci 2007. 
1103: 77-89. 
134 King, M. A., Covassin, L., Brehm, M. A., Racki, W., Pearson, T., Leif, J., 
Laning, J., Fodor, W., Foreman, O., Burzenski, L., Chase, T. H., Gott, B., 
Rossini, A. A., Bortell, R., Shultz, L. D. and Greiner, D. L., Human peripheral 
blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 
receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like 
disease and the role of host major histocompatibility complex. Clin Exp Immunol 
2009. 157: 104-118. 
135 King, M., Pearson, T., Shultz, L. D., Leif, J., Bottino, R., Trucco, M., Atkinson, 
M. A., Wasserfall, C., Herold, K. C., Woodland, R. T., Schmidt, M. R., Woda, B. 
A., Thompson, M. J., Rossini, A. A. and Greiner, D. L., A new Hu-PBL model for 
the study of human islet alloreactivity based on NOD-scid mice bearing a targeted 
mutation in the IL-2 receptor gamma chain gene. Clin Immunol 2008. 126: 303-314. 
136 Ali, N., Flutter, B., Sanchez Rodriguez, R., Sharif-Paghaleh, E., Barber, L. D., 
Lombardi, G. and Nestle, F. O., Xenogeneic graft-versus-host-disease in NOD-scid 
IL-2Rgammanull mice display a T-effector memory phenotype. PLoS One 2012. 7: 
e44219. 
137 Whitfield-Larry, F., Young, E. F., Talmage, G., Fudge, E., Azam, A., Patel, S., 
Largay, J., Byrd, W., Buse, J., Calikoglu, A. S., Shultz, L. D. and Frelinger, J. A., 
HLA-A2-matched peripheral blood mononuclear cells from type 1 diabetic patients, 
but not nondiabetic donors, transfer insulitis to NOD-scid/gammac(null)/HLA-A2 
transgenic mice concurrent with the expansion of islet-specific CD8+ T cells. 
Diabetes 2011. 60: 1726-1733. 
138 Brehm, M. A., Bortell, R., Diiorio, P., Leif, J., Laning, J., Cuthbert, A., Yang, C., 
Herlihy, M., Burzenski, L., Gott, B., Foreman, O., Powers, A. C., Greiner, D. L. 
and Shultz, L. D., Human immune system development and rejection of human islet 
allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice. 
Diabetes 2010. 59: 2265-2270. 
139 Izumi, T., Yokota-Hashimoto, H., Zhao, S., Wang, J., Halban, P. A. and 
Takeuchi, T., Dominant negative pathogenesis by mutant proinsulin in the Akita 
diabetic mouse. Diabetes 2003. 52: 409-416. 
 
  
 
  35 
CHAPTER 2: β-CELL-SPECIFIC IL-35 THERAPY SUPPRESSES ONGOING 
AUTOIMMUNE DIABETES1 
2.1 Summary 
IL-35 is a recently identified cytokine exhibiting potent immunosuppressive 
properties. The therapeutic potential and effects of IL-35 on pathogenic T effectors (Teff) 
and Foxp3+Treg, however, are ill-defined. We tested the capacity of IL-35 to suppress 
ongoing autoimmunity in NOD mice. For this purpose, an adeno-associated virus vector in 
which IL-35 transgene expression is selectively targeted to β cells via an insulin promoter 
(AAV8mIP-IL35) was used.  AAV8mIP-IL35 vaccination of NOD mice at a late preclinical 
stage of type 1 diabetes (T1D) suppressed β cell autoimmunity and prevented diabetes onset. 
Numbers of islet resident conventional CD4+ and CD8+ T cells, and DC were reduced within 
4 wks of AAV8mIP-IL35 treatment. The diminished islet T cell pool correlated with 
suppressed proliferation, and a decreased frequency of IFNγ-expressing Teff. Ectopic IL-35 
also reduced islet Foxp3+Treg numbers and proliferation, and protection was independent of 
induction/expansion of adaptive islet immunoregulatory T cells. These findings demonstrate 
that IL-35-mediated suppression is sufficiently robust to block established β cell 
autoimmunity, and support the use of IL-35 to treat T1D and other T cell-mediated 
autoimmune diseases.   
                                                            
1This chapter has been published in the European Journal of Immunology and represents a co-first author work. 
The original citation is as follows: Manzoor, F., Johnson, M.C., Li, C., Samulski, R.J., Wang, B., & Tisch, R. 
(2016). β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice. Eur J Immunol. 
doi:10.1002. 
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2.2 Introduction 
Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of 
the insulin producing β cells found in the pancreatic islets of Langerhans [1-4]. In the NOD 
mouse, a spontaneous model of T1D, the onset of diabetes is preceded by progressive 
infiltration of the islets that begins at 3-4 wks of age [1, 2]. This insulitis consists of various 
immune effectors including dendritic cells (DC), macrophages, B cells and T cells. Overt 
diabetes, typically first detected in NOD female mice at 12 wks of age, develops once >80% 
of β cell mass has been rendered nonfunctional or destroyed by ongoing inflammation [1]. 
The primary mediators of β cell destruction are CD4+ and CD8+ T cells, which mostly 
exhibit a type 1 effector phenotype marked by IFNγ production [1, 5]. Breakdown of β cell-
specific self-tolerance within the T cell compartment is complex, and is partly due to aberrant 
immunoregulation within the islets. Diminished local levels of IL-2 in NOD mice for 
instance, leads to a progressive loss in the number and function of islet-resident Foxp3-
expressing immunoregulatory CD4+ T cells (Foxp3+Treg) [6-9]. Temporal dysregulation of 
islet Foxp3+Treg in turn facilitates the expansion of pathogenic T effectors (Teff) leading to 
efficient β cell destruction [6-8]. The pathogenicity of islet Teff in NOD mice is further 
enhanced by a reduced sensitivity to Foxp3+Treg-mediated suppression [10, 11].  
IL-35 is a recently discovered member of the IL-12 cytokine family consisting of 
Epstein-Barr-virus-induced gene 3 (Ebi3) and IL-12α subunits [12]. Unlike other members 
of this cytokine family, IL-35 exhibits only immunosuppressive properties and has been 
shown to mediate protection in several diseases in both humans and mouse models [13-17]. 
IL-35 is secreted by and contributes to the suppressor function of Foxp3+Treg [18-20]. 
Additionally, IL-35 promotes differentiation of conventional CD4+ T cells into induced 
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regulatory Th35 suppressor (iTr35) cells, which secrete IL-35 but not IL-10 or TGFβ, and 
lack FoxP3 expression [21]. The inhibitory effects of IL-35 are largely mediated via cell 
cycle arrest in T cells, and by blocking Th1 and Th17 cell differentiation [20]. The use of 
Ebi3 deficient mice or a fusion protein has demonstrated a role for IL-35 in regulating 
autoimmunity and autoinflammation [12, 22]. Indeed, transgenic expression of IL-35 by β 
cells prior to the initiation of autoimmunity prevents diabetes in NOD mice [23]; how IL-35 
impacts islet infiltrating Teff and Foxp3+Treg once β cell autoimmunity is established, 
however, remains ill-defined.  
We and others have employed adeno-associated virus (AAV) vector gene delivery as 
a means to modify β cells and locally suppress islet autoimmunity [24, 25]. In general, AAV 
vectors are regarded as the safest and most efficient strategy to administer genes in vivo, and 
have been used to treat various genetic disorders in the clinic [26-30]. AAV vectors, in 
conjugation with a number of capsid protein serotypes with varying cell tropism and tissue 
specific promoters, offer an approach to selectively transduce distinct tissues and obtain 
long-term cell-specific transgene expression in vivo [27, 31, 32]. We have for instance, used 
an AAV vector containing a mouse preproinsulin II promoter (mIP) to transduce and 
selectively express IL-2 by β cells in NOD mice [24]. In this way, β cell autoimmunity is 
suppressed by increasing the islet Foxp3+Treg pool, while localizing IL-2 expression to the 
islets and therefore avoiding the complications associated with systemic IL-2 delivery [24, 
33]. Notably, AAV vectors also provide tools to dissect the local effects of various cytokines 
and factors on islet/tissue resident immune effectors during ongoing inflammation [24]. In 
the current study, an IL-35 expressing AAVmIP vector was used to test if the inhibitory 
properties of IL-35 are sufficiently robust to suppress ongoing β cell autoimmunity. We show 
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that targeting IL-35 expression to β cells in NOD mice at a late preclinical T1D stage 
prevents the development of diabetes. Protection is marked by significantly reduced numbers 
of islet T cells and DC, and a phenotypically distinct islet Foxp3+Treg pool, which in turn is 
needed to suppress CD4+ Teff differentiation.  
2.3 Material and Methods 
2.3.1 Mice 
NOD/LtJ, NOD.CB17-Prkdcscid/J (NOD.scid), NOD.Cg-Tg(TcraBDC2.5)1Doi 
Tg(TcrbBDC2.5)2Doi/DoiJ (NOD.BDC2.5), NOD.Cg-Tg(TcraTcrbNY8.3)1Pesa/DvsJ 
(NOD.8.3), NOD.129X1(Cg)-Foxp3tm2Tch/DVsJ (NOD.Foxp3GFP), NOD.BDC.Foxp3GFP, and 
NOD.129P2(C)-Tcratm1Mjo/DoiJ (NOD.Cαnull) mice were bred and maintained under specific 
pathogen-free conditions in an American Association for Laboratory accredited animal 
facility. NOD mice were diagnosed as diabetic after 3 consecutive blood glucose readings 
>250 mg/dL. All procedures were approved by the University of North Carolina Institutional 
Animal Use and Care Committee. 
2.3.2 AAV vector engineering, packaging and vaccination.  
Full-length cDNAs encoding murine Ebi3 and Il12α separated by an elastin gene 
linker (pUNO1-mIL35elasti; Invivogen) or EGFP were subcloned into a single stranded 
AAV plasmid [46] containing mIP, and packaged with serotype 8 capsid protein as 
previously described [34]. Briefly, HEK 293T cells were triple-transfected with adeno helper 
plasmid (pXX6-80), AAV8 capsid plasmid, and plasmids encoding IL-35 or GFP via 
polyethylamine. 72 h post-transfection, nuclear fractions were harvested, packaged vector 
purified by cesium chloride (RPI) gradient, and titer determined by Southern dot blot. 
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2.3.3 Islet isolation and insulitis scoring. 
Pancreases were perfused with 2 mg/mL of collagenase P (Roche) prepared in HBSS 
(Sigma) and digested for 25 min at 37°C. Islets were purified over a Lympholyte 1.1 
(Cedarlane) gradient, handpicked, and counted. Islet preparations from each individual 
animal consisted of 80-100 islets. Lymphocytes were collected from isolated islets following 
dissociation with an enzyme-free cell dissociation buffer (GIBCO) and filtered through a 70 
μm cell strainer.  
Formalin-fixed, paraffin embedded pancreases from non-diabetic 12 wk-old or 35 
wk-old AAV8mIP-IL35-treated NOD female mice were serially sectioned 100 μm apart, and 
stained with hematoxylin and eosin. Insulitis was then scored for a minimum of 50 islets for 
each individual pancreas. 
2.3.4 RNA, cDNA, and quantitative real time PCR.  
RNA from sorted islet/pancreas-resident Thy1.2+GFP- or GFP+ T cells was isolated 
using Trizol (Invitrogen) or RNeasy Mini Kit (Qiagen), and cDNA reverse transcribed with 
the Super Script III first strand kit (Invitrogen) following the manufacturer’s 
recommendations. Primers for Ebi3 and Il12a were as previously described [12]: Ebi3 
forward primer, AGCAGCAGCCTCCTAGCCT; Ebi3 reverse primer, 
ACGCCTTCCGGAGGGTC; Il12a forward primer, 
TGGCTACTAGAGAGACTTCTTCCACAA; Il12a reverse primer, 
GCACAGGGTCATCATCAAAGAC. Primers for IFNγ, TGFβ1, TNFα, IL-10, and IL-2 are 
as follows: IFNγ forward primer, TCAAGTGGCATAGATGTGGAAGAA; IFNγ reverse 
primer, TGGCTCTGCAGGATTTTCATG; IL-2 forward primer, 
CCTGAGCAGGATGGAGAATTACA; IL-2 reverse primer, 
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TCCAGAACATGCCGCAGAG; TNFα forward primer, 
CATCTTCTCAAAATTCGAGTGACAA; TNFα reverse primer, 
TGGGAGTAGACAAGGTACAACCC; IL-10 forward GCTCTTACTGACTGGCATGAG; 
IL-10 reverse primer, CGCAGCTCTAGGAGCATGTG; TGFβ1 forward primer, 
TGACGTCACTGGAGTTGTACGG; TGFβ1 reverse primer, 
GGTTCATGTCATGGATGGTGC. cDNA samples were amplified using a Maxima SYBR 
green master mix (Thermo Fisher) and an ABI Prism 7500 (Applied Biosystems). Relative 
mRNA expression was quantified by the comparative threshold (CT) method, where target 
mRNA expression is normalized to endogenous β-actin expression as determined by the 
formula 2–ΔΔCT. 
2.3.5 Flow cytometry.  
Single cell suspensions from various tissues were treated with rat anti-mouse 
CD16/32 (2.4G2) (BD Biosciences) to block Fc receptors and subsequently stained with 
titrated fluorochrome-conjugated Ab specific for: CD3 (145-2C11), CD4 (GK1.5), CD8 
(53.6.7), CD25 (PC61.5), CD62L (MEL-14), GITR (DTA-1), VAD-FMK (Promega), and 
Nrp-1 (3E12). Fluorochrome-conjugated H2Kd tetramers complexed to IGRP206-214 
(VYLKTNVFL) or control influenza hemagglutinin HA (IYSTVGSSL) peptide, and IAg7 
tetramers complexed to BDC mimetic (AHHPIWARMDA) or control 
(AMKRHGLDNYRGYSL) peptides were obtained from the National Institutes of Health 
Tetramer Core Facility. Intracellular staining of FoxP3 (FJK-16s; eBioscience), CTLA-4 
(UC10-4F10-11), Bim (Cell Signaling Technology) and Bcl-2 (3F11; BD Biosciences) was 
done using the Fix/Perm and Perm/Wash reagents (eBioscience) according to the 
manufacturer’s recommendations.  
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For intracellular cytokine staining, lymphocytes were stimulated with 500 ng/ml 
PMA (Sigma) and 1000 ng/ml ionomycin (Sigma) for 5 h at 37°C, with 10 μg/ml Brefeldin 
A (Sigma) added for the last 4 h of incubation. After surface staining, cells were fixed and 
permeabilized with the Fix/Perm kit (eBioscience) and stained for intracellular IFNγ 
(XMG1.2).  
BrdU incorporation was analyzed via flow cytometry as described previously [47]. 
Animals were given an i.p. injection of 2 mg BrdU (Sigma), organs harvested 24 h later, and 
analyzed using mouse anti-BrdU PE Ab (BD Biosciences).   
In addition, NOD.Foxp3GFP female mice were given i.p. 500 μg of PC61 5.3. 
(BioXcell) or rat IgG1 isotype control Ab. Organs were harvested 12 d later and biotinylated 
anti-CD25 (7D4) used for flow cytometric analysis.  
Data were acquired on a Becton-Dickinson LSRII and Cyan flow cytometer 
(DakoCytomation) and analyzed using FlowJo Software and Summit software (Treestar). 
2.3.6 Cell adoptive transfer. 
Thy1.2+ cells (5x106) from spleens of non-diabetic NOD.Foxp3GFP female mice were 
sorted via FACS and injected i.p. into AAV8mIP-GFP or AAV8mIP-IL35 treated NOD.scid 
female mice. Purity of sorted Thy1.2+ cells was >95%. 
2.3.7 In vitro suppressor assay. 
Pancreatic single cell suspensions prepared from NOD.BDC.FoxP3GFP female mice 
were stained with anti-CD4, and CD4+GFP+ T cells sorted on FACSAria II (BD Biosciences) 
at a cell purity of >95% post-sort. Splenocytes from NOD.Cα-/- mice were used as APC and 
pulsed with 1 μg/mL BDC peptide. CD4+CD25- T cells enriched from spleens of 
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NOD.BDC2.5 mice using CD4+CD25+ Regulatory T cell Isolation Kit (Milltenyi Biotec), 
were labeled with 5 μM Cell Trace Violet (CTV; Invitrogen) and used as responders. BDC 
CD4+CD25- T cells (3x104) were co-cultured with varying ratios of CD4+GFP+ T cells and 
APC (3x104) for 72 h at 37°C. Proliferation was assessed by dilution of CTV measured via 
flow cytometry. 
2.3.8 Statistical analysis.  
Graphpad Prism software was used to perform all statistical analyses. 
2.4 Results 
2.4.1 β cell-specific IL-35 expression prevents overt diabetes at a late preclinical stage in 
NOD mice.  
To assess the therapeutic potential of IL-35, AAVmIP-IL35 was engineered in which 
Ebi3 and Il12a are driven by mIP to restrict expression to β cells. In our hands long-term 
(e.g. up to 1 yr) AAV8mIP transgene expression is detected in β cells but not other tissues 
including the liver, thymus and spleen [24]. The AAV capsid serotype 8 protein was used to 
package AAVmIP-IL35 to increase β cell transduction efficiency in vivo [25, 34, 35]. 
Injection of NOD mice with AAV8mIP-IL35 resulted in a dose-dependent increase in Ebi3 
and IL-12α mRNA levels in pancreatic islets (Fig. 2.1A). To determine if ectopic IL-35 
suppressed ongoing β cell autoimmunity, 12 wk-old NOD female mice, reflecting a late 
preclinical stage at which islets are heavily infiltrated, were vaccinated i.p. with AAV8mIP-
IL35, control AAV8mIP-GFP or were left untreated, and blood glucose levels monitored. 
The majority (>70%) of untreated and AAV8mIP-GFP-treated control NOD mice developed 
diabetes with a similar time of onset by 35 wks of age (Fig. 2.1B). In contrast, a dose-
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dependent increase in diabetes-free NOD female mice was observed following AAV8mIP-
IL35 vaccination (Fig. 2.1B).  After receiving 2.5x1010 and 10x1010 vector particles (vp) of 
AAV8mIP-IL35, 60% and 79% of NOD female mice remained nondiabetic, respectively 
(Fig. 2.1B).   Furthermore, analyses of pancreatic sections from nondiabetic 35 wk-old NOD 
female mice treated with 10x1010 vp AAV8mIP-IL35 showed a frequency of insulitis 
equivalent to that seen in unmanipulated, nondiabetic 12 wk-old NOD female mice (Fig. 
2.1C). These results demonstrate that β cell-specific expression of IL-35 suppresses the 
progression of insulitis and the development of overt diabetes. 
2.4.2 Ectopic IL-35 expression reduces islet infiltration.  
To gain insight into the mechanism(s) of protection, the effect of β cell-specific IL-35 
on islet infiltrating cells was examined. NOD female mice 12 wks of age were vaccinated 
with 10x1010 vp of AAV8mIP-IL35 or AAV8mIP-GFP, and islets isolated 4 wks later.  In 
agreement with the insulitis data for animals followed long-term (Fig. 2.1C), islet but not 
splenic T cell numbers were reduced in AAV8mIP-IL35-treated animals (Fig. 2.2A,B). 
Specifically, numbers of conventional CD4+ and CD8+ T cells infiltrating the islets were 
reduced 2.6- and 2.3-fold, respectively, in AAV8mIP-IL35 versus AAV8mIP-GFP NOD 
mice (Fig. 2.2A). The latter was reflected by a decreased frequency of H2Kd-IGRP and IAg7-
BDC tetramer staining CD8+ T cells and CD4+ T cells, respectively, in the islets but not the 
draining pancreatic lymph nodes (PLN) or spleen (Fig. 2.2C,D). A trend in reduced islet 
Foxp3+Treg numbers was also detected in AAV8mIP-IL35 NOD mice, which correlated with 
no marked change in the frequency of Foxp3+Treg among the islet CD4+ T cell pool (Fig. 
2.2A,E). These results indicated that the impact of ectopic IL-35 was local, consistent with 
findings obtained in NOD mice vaccinated with an IL-2 expressing AAV8mIP vector [24].  
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Numbers of islet resident non-T cell types were also reduced by β cell-specific IL-35 
expression. Islet DC were decreased ~4-fold in the AAV8mIP-IL35 versus control groups 
(Fig. 2.2F). This decrease was seen for CD11c+ Sirpα+ and Sirpα- DC subsets, as well as 
plasmacytoid DC (pDC) (Fig. 2.2F). No marked changes in DC frequency (Fig. 2.2F) or 
maturation, based on expression levels of IAg7, H2Kd and CD80 were detected for the 
respective DC subsets (data not shown). Together, these results demonstrate that β cell-
specific IL-35 affects islet cellularity, marked by reduced numbers of conventional CD4+ and 
CD8+ T cells, Foxp3+Treg, and other islet resident immune effectors such as DC. 
2.4.3 Ectopic IL-35 expression suppresses islet T cell expansion.   
A reduced islet T cell pool may be due to suppressed proliferation, and/or increased 
cell death. To examine the proliferative status of islet T cells, 12 wk-old NOD female mice 
were vaccinated with AAV8mIP-IL35 and AAV8mIP-GFP and 4 wks later, BrdU uptake 
measured. An ~2-4-fold reduction in BrdU incorporation by islet CD4+ and CD8+ T cells and 
Foxp3+Treg was detected in AAV8mIP-IL35-treated NOD mice (Fig. 2.3A), whereas 
proliferation of splenic T cells was unaffected (Fig. 2.3B). A similar decrease in BrdU 
incorporation was seen for islet CD4+ and CD8+ T cells in AAV8mIP-IL35-vaccinated TCR 
transgenic NOD.BDC2.5 and NOD.8.3 mice, respectively (Fig. 2.3C). Based on VAD-FMK 
staining, however, ectopic IL-35 had no effect on the frequency of apoptotic CD4+ and CD8+ 
T cells or Foxp3+Treg in the pancreas of NOD mice 10 d post-vaccination (Fig. 2.S1). 
Similarly, the frequency of islet CD4+ and CD8+ T cells and Foxp3+Treg expressing the pro-
apoptotic molecule Bim or the anti-apoptotic molecule Bcl-2 was unaffected by AAV8mIP-
IL35-treatment relative to controls (Fig. 2.S1). 
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In a second model, NOD.scid mice were treated with 10x1010 vp of AAV8mIP-IL35 
or AAV8mIP-GFP, and 4 wks later injected with FACS-sorted splenic T cells (Thy1.2+) 
from NOD.Foxp3GFP donors. At 12 and 21 d post-transfer, a similar number of CD4+ and 
CD8+ T cells and an equivalent frequency of BrdU+ T cells were detected in the spleen of the 
2 experimental groups (Fig. 2.S2). In contrast, a decrease in both the number of CD4+ and 
CD8+ T cells and percentage of proliferating cells was detected in the islets of AAV8mIP-
IL35- versus AAV8mIP-GFP-treated recipients at the respective times post-transfer (Fig. 
2.3D). At 6 d post-transfer, however, a similar number and frequency of BrdU+ T cells were 
detected in AAV8mIP-IL35 and AAV8mIP-GFP vaccinated NOD.scid recipients indicating 
that T cell trafficking into the islets was not markedly affected by IL-35 (data not shown). 
These results demonstrate that ectopic IL-35 effectively suppresses islet T cell proliferation 
and expansion independent of induction of apoptosis. 
2.4.4 β cell-specific IL-35 expression reduces the proinflammatory milieu of the islets.  
Whether ectopic IL-35 also induced qualitative changes within the islet T cell pool 
was assessed. Flow cytometric analyses showed that the frequency of pancreatic IFNγ+CD4+ 
Teff was decreased ~2 fold by ectopic IL-35 (Fig. 2.4A). Somewhat surprisingly, the 
frequency of IFNγ+CD8+ Teff was unaffected by AAV8mIP-IL35 (Fig. 2.4A). Expression of 
IFNγ mRNA by pancreatic conventional (GFP-) T cells FACS-sorted from NOD.Foxp3GFP 
female mice was reduced by ectopic IL-35 relative to the control group (Fig. 2.S3).  
A diminished pool of IFNγ+ CD4+ Teff may have in part been due to 
induction/expansion of adaptive CD4+ Treg, such as iTr35 cells. Accordingly, 10 wk-old 
female NOD.BDC.Foxp3GFP mice were treated with AAV8mIP-IL35, conventional  (GFP-) T 
cells FACS-sorted 4 wks later, and cytokine mRNA expression measured by qRT-PCR. 
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Notably, naïve BDC CD4+ T cells are found at a relatively high frequency in the islets 
(~30%), which in turn may serve as precursors for iTr35 cells or other adaptive Treg subsets. 
Consistent with the data for AAV8mIP-IL35 treated NOD.Foxp3GFP mice (Fig. 2.S3), the 
expression of IFNγ mRNA by pancreatic BDC CD4+ T cells was reduced 2-fold by ectopic 
IL-35 (Fig. 2.4B). Furthermore, Ebi3 and IL-12α transcripts were decreased in BDC CD4+ T 
cells relative to the control group (Fig. 2.4B), indicating limited (if any) IL-35-mediated 
iTr35 cell differentiation or expansion in AAV8mIP-IL35 vaccinated mice. Ectopic IL-35 
also failed to increase BDC CD4+ T cell expression of IL-10 and TGFβ1 mRNA (Fig. 2.4B). 
Similar results were obtained in female NOD.Foxp3GFP mice vaccinated with AAV8mIP-
IL35 (Fig. 2.S3).  
Next, the effects of ectopic IL-35 on the phenotype and function of islet Foxp3+Treg 
were examined in 12 wk-old NOD female mice. CD25 and FoxP3 expression based on MFI 
(Fig. 2.5A), as well as the frequency of GITR+ and CD62Lhi islet Foxp3+Treg were 
unaffected by IL-35 (Fig. 2.5B); CD62Lhi Foxp3+Treg typically exhibit enhanced suppressor 
activity [9, 36-38]. In addition, ectopic IL-35 had no effect on the frequency of Foxp3+Treg 
expressing neuropilin-1 (Nrp-1), a marker for thymic-derived Foxp3+Treg (Fig. 2.5B) [39].  
However, a 3-fold increase in the frequency of CTLA-4+ islet Foxp3+Treg coupled with a 2-
fold increase in CTLA-4 MFI was observed in AAV8mIP-IL35-vaccinated NOD mice (Fig. 
2.5C). To assess islet Foxp3+Treg suppressor activity, NOD.BDC.Foxp3GFP mice were 
treated with AAV8mIP-IL35, pancreatic CD4+GFP+ T cells FACS-sorted, and co-cultured 
with conventional BDC CD4+ T cells and sBDC peptide-pulsed APC. No difference in 
suppressor activity was detected between Foxp3+Treg isolated from AAV8mIP-IL35 versus 
control animals (Fig. 2.5D). Furthermore, with the exception of IL-10 mRNA which was 
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reduced, similar levels of Ebi3, IL-12α, and TGFβ1 mRNA were detected in FACS-sorted 
pancreatic Foxp3+Treg (GFP+) from AAV8mIP-IL35 and control NOD.BDC.Foxp3GFP mice 
(Fig. 2.5E).  
To investigate the relative contribution of Foxp3+Treg in vivo following ectopic IL-35 
expression, AAV8mIP-IL35 vaccinated NOD.Foxp3GFP female mice were treated with PC61, 
an anti-CD25 Ab known to deplete and/or block activity of Foxp3+Treg [40-42]. Islet and 
splenic Foxp3+Treg frequency and number were reduced at least 2-fold 12 d by PC61 
compared to the isotype Ab control group (Fig. 2.S4). No difference in the number of islet 
CD4+ and CD8+ T cells was detected between AAV8mIP-IL35 vaccinated animals treated 
with PC61 and isotype control Ab (Fig. 2.5F).  On the other hand, the frequency and MFI of 
intracellular IFNγ for islet IFNγ+CD4+ but not IFNγ+CD8+ T cells were increased in PC61 
versus control group (Fig. 2.5G). In contrast, no further increase in IFNγ+CD4+ Teff or IFNγ 
MFI was detected in the islets of AAV8mIP-GFP vaccinated animals treated with PC61 (Fig. 
2.5G). The latter suggests that Foxp3+Treg play only a limited role at this late preclinical 
stage of T1D. These results demonstrate that the frequency of islet IFNγ+CD4+ Teff but not 
IFNγ+CD8+ Teff is decreased in AAV8mIP-IL35 vaccinated NOD mice, which in turn is 
mediated, at least in part, by islet Foxp3+Treg. Furthermore, protection induced by ectopic 
IL-35 is independent of adaptive Treg (e.g. iTr35 cells). 
2.5 Discussion 
Earlier work by the Vignali group demonstrated that transgenic NOD mice expressing 
IL-35 by β cells throughout ontogeny remain diabetes free [23]. Our findings show that the 
anti-inflammatory properties of ectopic IL-35 are sufficiently robust to suppress ongoing β 
cell autoimmunity at late preclinical T1D, and prevent the onset of diabetes. Notably, β cell-
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specific IL-35 had quantitative and qualitative effects locally on CD4+ and CD8+ Teff, 
Foxp3+Treg and other immune effectors residing in the islets.  
A key aspect of the protection induced by ectopic IL-35 was the reduction in islet 
infiltrating β cell-specific CD4+ and CD8+ Teff (Figs. 2.1C, 2.2A,B). Insulitis in 35 wk-old 
nondiabetic NOD mice vaccinated with AAV8mIP-IL35 was the equivalent of a 12 wk-old 
animal, indicating that progression of islet infiltration was suppressed shortly after treatment. 
Indeed, conventional T cells were decreased ~4-fold within 4 wks of AAV8mIP-IL35 
treatment (Fig. 2.2A). Analogous results were seen in the islets of AAV8mIP-IL35-treated 
NOD.scid mice after transfer of NOD T cells (Fig. 2.3D).  The reduction in islet CD4+ and 
CD8+ T cells induced by ectopic IL-35 correlated with suppressed T cell proliferation but no 
effect on the frequency of apoptotic islet T cells (Fig. 2.S1). Bettini et al. similarly reported 
diminished proliferation of pancreatic Teff in IL-35 transgenic NOD mice [23]. In addition to 
T cells, the number of islet DC (Fig. 2.2F) as well as islet B cells (data not shown) was 
reduced in AAV8mIP-IL35-vaccinated mice. A decrease in the islet APC pool is expected to 
aid in limiting local T cell stimulation, expansion and/or Teff differentiation. Whether 
ectopic IL-35 directly affected islet APC is unclear, although the absence of any change in 
activation and maturation suggests that islet DC were likely affected by IL-35 in an indirect 
manner. In this scenario, IL-35 suppresses CD4+ T cell-derived pro-inflammatory cytokines 
(e.g. IFNγ, TNFα) which indirectly downregulates local chemokines and integrins needed for 
efficient retention of islet APC, as well as conventional T cells and Foxp3+Treg.  This and 
the possibility that IL-35 indeed has direct effects on DC (and B cells) are currently being 
assessed.  
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Under the appropriate conditions IL-35 promotes differentiation of iTr35 cells. Our 
findings, however, indicate that ectopic IL-35 failed to induce detectable iTr35 cell 
differentiation. Levels of Ebi3 and IL-12α mRNA were in fact reduced in islet CD4+ T cells 
from AAV8mIP-IL35 mice (Fig. 2.4B; Fig. 2.S3). Vignali and colleagues similarly reported 
a lack of iTr35 cell differentiation in the pancreas of IL-35 transgenic NOD mice [23]. These 
results argue against a key role for islet iTr35 cells in AAV8mIP-IL35-induced protection.  
Lack of an increase in iTr35 cells may be attributed to insufficient local levels of IL-10, 
which is needed in convert with IL-35 to drive efficient subset differentiation [21, 43]. No 
change in the expression of TGFβ1 and IL-10 by islet CD4+ T cells in AAV8mIP-IL35-
treated animals (Fig. 2.4B) also indicates a minimal (if any) role for other subsets of adaptive 
(FoxP3-) CD4+ Treg in regulating β cell autoimmunity locally.  
The in vivo effects of IL-35 on Foxp3+Treg in general, and specifically within the 
islets are ill-defined. Notably, ectopic IL-35 was seen to influence the islet Foxp3+Treg pool 
in a variety of ways. There was a trend towards a reduction in islet Foxp3+Treg numbers, 
which corresponded with decreased proliferation (Figs. 2.2, 2.3), also reported in IL-35 
transgenic NOD mice [23]. Similar to conventional CD4+ T cells, apoptosis was not 
increased and the frequency of Bcl-2+ and Bim+ cells unchanged in islet Foxp3+Treg (Fig. 
2.S1). Furthermore, levels of CD25 and FoxP3 expression, and the frequency GITR+, 
CD62Lhi and Nrp-1+ Foxp3+Treg were similar between AAV8mIP-IL35 and control groups 
(Fig. 2.5). On the other hand, both the MFI (~2-fold) and frequency (~3-fold) of CTLA-4-
expressing islet Foxp3+Treg were significantly increased in AAV8mIP-IL35 vaccinated 
animals (Fig. 2.5C). Since iTr35 cells are characterized in part by a CTLA-4hi phenotype 
[21], it is possible that IL-35R signaling regulates CTLA-4 expression in the appropriate T 
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cell subset. Other reported effects of IL-35 on Foxp3+Treg include down-regulation of 
expression of proinflammatory cytokines, and up-regulation of the transcriptional factor Eos, 
which is known to regulate Foxp3+Treg suppressor activity [44].  Despite the increase in 
CTLA-4, a potent effector molecule, the in vitro suppressor activity of pancreatic 
Foxp3+Treg from AAV8mIP-IL35 mice was not elevated (Fig. 2.5D). This result is 
consistent with a significant decrease in IL-10 expression but no marked increase in the 
expression of TGFβ1 or IL-35 (Ebi3, IL-12α) by pancreatic Foxp3+Treg from AAV8mIP-
IL35 vaccinated mice  (Fig. 2.5E). Results with PC61 Ab treatment, however, suggest that 
islet Foxp3+Treg play a selective role in suppressing differentiation of pathogenic CD4+ Teff 
in vivo. The frequency of islet IFNγ+CD4+ but not IFNγ+CD8+ Teff was increased ~2-fold in 
AAV8mIP-IL35 vaccinated mice treated with PC61 Ab (Fig. 2.5G). The latter is consistent 
with >2-fold decrease in islet IFNγ+CD4+ T cells not seen for IFNγ+CD8+ following 
AAV8mIP-IL35 treatment (Fig. 2.4A). It is unclear why only expansion/differentiation of 
IFNγ+ CD4+ Teff is affected by Foxp3+Treg. One possibility is that IL-35 enhances the 
sensitivity of CD4+ T cells to Foxp3+Treg-mediated suppression. The qualitative changes 
induced by IL-35 (Fig. 2.5) may also result in a Foxp3+Treg pool that is more effective at 
suppressing CD4+ Teff expansion/ differentiation in vivo. Overall, however, our results 
support a model in which the dominant effect of ectopic IL-35 is to directly suppress 
expansion of islet CD4+ and CD8+ T cells with islet Foxp3+Treg playing a selective 
suppressor role. As discussed above a diminished pool of islet resident DC and APC would 
also be expected to aid in limiting T cell expansion.     
Finally, our studies highlight the therapeutic potential of IL-35 either as a 
monotherapy or in combination with other immunotherapies to suppress ongoing β cell 
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autoimmunity and T1D. The suppressor activity of IL-35 readily blocks the expansion of 
pathogenic CD4+ and CD8+ Teff. A recent study also showed that systemic administration of 
recombinant IL-35 prevents diabetes in a multiple low dose streptozotocin model of T1D, 
and induces remission in a portion of new onset diabetic NOD mice; recurrent diabetes 
develops, however, once IL-35 therapy is terminated [44]. On the other hand, i.v. injection of 
8 wk-old NOD female mice with an adenovirus recombinant encoding IL-35 had no marked 
protective effect [45]; whether sufficient systemic levels of IL-35 were achieved, however, is 
unclear. Nevertheless, systemic application of IL-35, particularly over an extended period, 
may lead to suppression of normal immune function. Indeed, unwanted systemic effects are a 
common concern for most cytokine-based immunotherapies. Our study provides further 
evidence that the use of AAV vectors is an effective strategy to manipulate the expression 
and tolerogenic properties of a cytokine in a highly tissue-specific manner. Engineering 
capsid proteins with enhanced tropism for certain cell types (e.g. β cells) and which lack 
reactivity to neutralizing Ab, coupled with sensitive inducible transgene systems will greatly 
enhance the clinical application of AAV vectors and cytokine therapy. 
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Figure 2.1: β  cell-specific expression of IL-35 at a late preclinical stage prevents the 
onset of diabetes. 12 wk-old NOD female mice were treated with AAV8mIP-IL35, 
AAV8mIP-GFP, or left untreated. (A) Ebi3 and IL12α mRNA levels were compared 
between pancreases/islets from AAV8mIP-IL35 and untreated cohorts; the ratio of 
expression for the respective genes between AAV8mIP-IL35 and untreated controls is 
depicted. Data presented are the average of 2 separate experiments. ***p<0.001 (Student’s t 
test) ±SEM. (B) Cohorts treated with AAV8mIP-IL35 (10x1010 vp, n=14; 2.5x1010 vp, n=5), 
AAV8mIP-GFP (10x1010 vp, n=10), or left untreated (n=10) were monitored for overt 
diabetes. **p<0.01, ***p<0.001 (Kaplan-Meier log-rank test). (C) Insulitis was determined 
in hematoxylin and eosin stained pancreatic sections of 35-wk old non-diabetic NOD female 
mice treated with AAV8mIP-IL35 (n=6) and compared to 12-wk old NOD female mice 
(n=8). Insulitis was scored as the percentage of islets with no insulitis, peri-insulitis, <50% 
intra-insulitis, and >50% intra-insulitis. 
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Figure 2.2: Ectopic IL-35 expression reduces islet infiltrating T cells and DC.  (A-E) 
Groups of 3-4 12 wk-old NOD female mice were treated with 10x1010 vp of AAV8mIP-
IL35, AAV8mIP-GFP, or left untreated, and 4 wks later islets, spleen and/or PLN examined. 
The number of live CD3+-gated CD4+, CD8+, and FoxP3+ cells were determined in the (A) 
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islets, and (B) spleen. Data presented are average of 5 independent experiments. *p<0.05, 
**p<0.01 (Student’s t test) ±SEM.  Live CD3+ cells were gated on and the frequency of islet, 
PLN, and splenic (C) H2Kd-IGRP+ CD8+ and (D) IAg7-BDC+ CD4+FoxP3- T cells 
determined. Representative flow plots for tetramer staining of islet CD8+ and CD4+ T cells 
are provided. Staining of control H2Kd-HA and IAg7-control peptide was typically <6% of 
CD8+ and CD4+ T cells, respectively.  Data represent average of 2 independent experiments. 
(E) Frequency of islet and splenic CD3+-gated FoxP3+ cells. Data represent average of 5 
independent experiments. (F) CD11c+ cells were gated on and the number of bulk islet 
CD11c+ DC, and number and frequency of islet CD11c+Sirpα+ DC, CD11c+Sirpα- DC and 
CD11c+B220+ pDC measured via flow cytometry. Data presented are average of 2 separate 
experiments. ***p<0.001, **p<0.01, *p<0.05 (Student’s t test) ±SEM. 
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Figure 2.3: β  cell-specific IL-35 reduces proliferation of islet resident conventional T 
cells and Foxp3+Treg. Groups of 3-5 (A,B) 12 wk-old NOD female mice, (C) 6 wk-old 
NOD.BDC2.5 and NOD.8.3 female or (D) 10 wk-old NOD.scid female mice were treated 
with 10x1010 vp of AAV8mIP-IL35, AAV8mIP-GFP, or left untreated. (A-D) 4 wk post-
AAV vector treatment, live CD3+ cells were gated on and BrdU incorporation by CD4+, 
CD8+, and CD4+FoxP3+ cells determined via flow cytometry in the (A) islets and (B) spleen 
of NOD mice, and in (C) NOD.BDC2.5 and NOD.8.3 mice. *p<0.05 (Student’s t test) 
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±SEM; data represent average of 3 independent experiments. (D) NOD.FoxP3GFP-
derivedThy1.2+ T cells were adoptively transferred and BrdU incorporation and number of 
live islet CD3+CD4+Foxp3- and CD3+CD8+ T cells determined via flow cytometry 12 d and 
21 d post-transfer. **p<0.01, *p<0.05 (Student’s t test) ±SEM; data represent average of 2 
independent experiments. 
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Figure 2.4: Ectopic IL-35 induces a qualitatively distinct pool of islet conventional T 
cells. (A, B) Groups of 3-4 NOD or NOD.BDC.Foxp3GFP female mice 12 wks of age were 
treated with AAV8mIP-IL35 or left untreated, and spleen and pancreas examined 4 wks later. 
(A) Live CD3+ cells were gated on and pancreatic CD4+FoxP3- and CD8+ T cells assessed for 
intracellular IFNγ. **p<0.01 (two-way ANOVA with Bonferroni posttest) ±SEM; data 
represented are average of 2 separate experiments. (B) Groups of four 10 wk-old 
NOD.BDC.Foxp3GFP female mice were treated with 10x1010 vp of AAV8mIP-IL35 or left 
untreated, and 4 wks later Thy1.2+CD3+GFP- cells sorted from the pancreas, and mRNA 
levels of Ebi3, IL-12α, IFNγ, TGFβ, and IL-10 compared. *p<0.05 (Student’s t test) ±SEM; 
data represented are average of 2 separate experiments.  
  58 
 
Figure 2.5: Qualitatively distinct Foxp3+Treg are needed to suppress CD4+ Teff in 
AAV8mIP-IL35 treated mice. Groups of 3-4 12 wk-old (A-C) NOD, (D,F,G) 
NOD.Foxp3GFP, or (E) 10 wk-old NOD.BDC.Foxp3GFP female mice were treated with 
10x1010 vp of AAV8mIP-IL35 or AAV8mIP-GFP or left untreated, and 4 wks later, islet and 
splenic CD3+ T cells analyzed. (A) Level of CD25 and FoxP3 expression among islet 
CD3+CD4+ T cells. (B) Frequency of GITR, CD62L, and Nrp-1 expressing CD3+CD4+FoxP3+ 
cells. (C) The frequency and MFI for CTLA-4 expression by islet CD3+CD4+FoxP3+ cells. 
*p<0.05, **p<0.01 (Student’s t test) ±SEM; data representative are average of > 2 
independent experiments. (D) In vitro suppressor activity of pancreatic FoxP3+/GFP+ BDC 
CD4+ T cells sorted from AAV8mIP-IL35 or untreated animals assessed via flow cytometry. 
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(E) Cytokine mRNA levels were measured in Thy1.2+CD3+GFP+ cells sorted from 
NOD.BDC.Foxp3GFP pancreases, and the fold-difference between AAV8mIP-IL35 and 
control mice determined. ***p<0.001 (Student’s t test) ±SEM; data represented are average 
of 2 independent experiments. (F-G) 4 wks post-AAV8mIP-IL35 or AAV8mIP-GFP 
treatment, mice received PC61 or isotype control Ab, 12 d later live CD3+GFP-(FoxP3-) cells 
in the islets were gated on, and the (F) number and (G) frequency of IFNγ+ CD4+ and CD8+ T 
cells by CD4+ and CD8+ T cells determined. *p<0.05 (Student’s t test) ±SEM; data 
represented are average of 2 independent experiments. 
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Figure 2.S1: AAV8mIP-IL-35 treatment has no effect on T cell apoptosis (A) 10 d post-
AAV vector administration, CD3+ cells were gated on and VAD-FMK staining of pancreatic 
CD4+FoxP3-, CD8+FoxP3- and CD4+FoxP3+ cells assessed via flow cytometry in 
NOD.Foxp3GFP female mice. 4 wks post-AAV vector administration, Bim (B) and Bcl-2 (C) 
expression of islet CD3+CD4+FoxP3-, CD3+CD8+FoxP3-, and CD3+CD4+FoxP3+ cells was 
assessed via flow cytometry. Data are representative of two pooled independent experiments 
consisting of groups of 3-5 female mice. 
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Figure 2.S2: Proliferation and number of splenic CD4+ and CD8+ T cells is unchanged 
between AAV8mIP-IL35 and AAV8mIP-GFP treated adoptive transfer recipients. 
Groups of 3-6 NOD.scid female mice 10 wks of age were vaccinated with AAV8mIP-GFP or 
AAV8mIP-IL35. Thy1.2+ T cells were adoptively transferred 4 weeks following AAV 
administration. 12 d and 21 d post-transfer, BrdU incorporation (A) and number (B) of live 
splenic CD3+-gated T cells determined by flow cytometry. Data are representative of two 
pooled independent experiments ±SEM. 
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Figure 2.S3: AAV8mIP-IL35 treatment results in distinct subset of pancreatic 
conventional T cells. Groups of 3-4 NOD.Foxp3GFP female mice 12 wks of age were treated 
with AAV8mIP-IL35 or left untreated and examined 4 wks later. Thy1.2+GFP- T cells were 
sorted from the pancreas, and fold difference for Ebi3, IFNγ, TGFβ, and TNFα mRNA 
expression between AAV8mIP-IL35 versus control mice determined. 
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Figure 2.S4: Frequency and number of Foxp3+Treg in PC61 treated AAV8mIP-IL35 
vaccinated animals . 10-12 wk old NOD.Foxp3GFP females were treated with AAV8mIP-
IL35 or AAV8mIP-GFP. 4 wk post-AAV vector administration mice were given PC61 or 
isotype control Ab and islets and spleens were analyzed 12d later. Islets (A) and spleen (B) 
were assessed for number and frequency of Foxp3+ Treg. ***p<0.001, **p<0.01, *p<0.05 
(Student’s t test) ±SEM; data are representative of 2 pooled independent experiments. 
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Figure 2.6: AAV8mIP-IL35 immunotherapy. IL-35 expression by β cells following adeno-
associated viral vector immunotherapy inhibits proliferation and reduces islet CD4+ and 
CD8+ T cells, and Foxp3+Treg; islet dendritic cells are also decreased. Islet Foxp3+Treg 
selectively inhibit IFNγ production by CD4+ T cells, further limiting local inflammation and 
suppressing autoimmune diabetes in NOD mice.  
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CHAPTER 3: USING AAV-MEDIATED IL-2 THERAPY TO MANIPULATE 
HUMAN IMMUNOREGULATORY T CELL IN A HUMANIZED MOUSE MODEL 
3.1 Summary  
Interleukin-2 (IL-2) is a pleiotropic cytokine necessary for maintenance of 
Foxp3+Treg and effector T cells (Teff). Defects in Foxp3+Treg survival, function, and fitness 
linked to dysregulation of the IL-2-IL-2 receptor (IL-2R) axis have been implicated in the 
development of type 1 diabetes (T1D) in both humans and mice. To study the in vivo effects 
of IL-2 on human FOXP3+Treg in general, as well as better define differences in the in vivo 
response of FOXP3+Treg derived from T1D and healthy non-diabetic (ND) individuals, we 
established a model system employing: i) humanized NRG mice engrafted with peripheral 
blood human mononuclear cells (PBMC) (hu-PBL-NRG) and ii) an adeno-associated virus 
(AAV) vector gene transfer approach to ectopically express human IL-2 in β cells in vivo. 
Our findings indicate that β cell-specific human IL-2 expression results in a tissue-specific 
increase in the number and frequency of pancreatic FOXP3+Treg in hu-PBL-NRG mice 
derived from both T1D and ND PBMCs. Furthermore, the expanded FOXP3+Treg pool 
exhibited enhanced suppressive capability. These results indicate that ectopic human IL-2 
expression leads to a tissue-specific increase in FOXP3+Treg, thereby circumventing the 
deleterious effects associated with systemic delivery of IL-2.  
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3.2 Introduction 
Type 1 diabetes (T1D) is an autoimmune disease mediated by T cell-mediated 
destruction of the insulin-producing β cells of the islets of Langerhans [1, 2].  The 
autoimmune response of T1D is marked by infiltration of the pancreatic islets with β cell-
specific pathogenic effector T cells (Teff) and protective Foxp3-expressing 
immunoregulatory T cells (Foxp3+Treg). Studies in NOD mice have demonstrated that 
aberrant Foxp3+Treg regulation leads to breakdown in β cell self-tolerance and destruction 
[3]. Foxp3+Treg are characterized by high expression of interleukin-2 receptor α (IL-2Rα; 
CD25); and are dependent upon IL-2 for survival, expansion, and maintenance of foxp3 gene 
expression [4, 5].  
 Reduced local levels of IL-2 in NOD mice are associated with reduced frequency and 
number of Foxp3+Treg in islets of NOD mice [6]. IL-2 binds to the trimeric IL-2R and 
signals in a signal transducer and activator of transcription 5 (STAT5)-dependent manner. 
Engagement of IL-2R upon binding to IL-2 initiates signaling through the Janus-kinase 
(JAK)-STAT signaling pathway. Responsiveness of Foxp3+Treg to IL-2 directly correlates 
with level of phosphorylation of STAT5 molecule.  Genome wide association studies 
(GWAS) have identified several alleles responsible for deficiencies in the IL-2/IL-2R 
signaling pathway in humans and mice [6-8]. Reduced IL-2 signaling leads to Foxp3+Treg 
dysfunction and inability to keep Teff in check. In fact, several genes in the IL-2/IL-2R 
signaling pathway, including genes in the idd3 susceptibility locus, have been implicated in 
conferring susceptibility to T1D development in both NOD mice and humans [5, 9-12]. 
Therefore, IL-2 can be used as a means to circumvent the dysfunctional profile of 
Foxp3+Treg and enhance suppressor activity. Although the NOD mouse model of T1D has 
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been crucial for our understanding of T1D pathogenesis, there remain inadequacies in 
utilizing a murine model to study human disease. Numerous therapies that have shown 
promising results in “curing” disease in NOD mice have shown disappointing results in 
patients [13, 14]. Accordingly, there is need to directly investigate the effects of a given 
immunotherapy on human immune cells in vivo is of prime importance.  
Human FOXP3+Treg are phenotypically diverse and, similar to murine Foxp3+Treg, 
are essential for maintaining self-tolerance and curbing autoimmunity. In humans, 
FOXP3+Treg are delineated by expression of CD4, CD25, and FOXP3 and lack of 
expression of CD127 [15]. Human FOXP3+Treg derived from T1D individuals are less 
responsive to IL-2 marked by diminished IL-2R signaling [5, 16]. Although T1D individuals 
do not present with reduced FOXP3+Treg frequencies in the periphery, there are significant 
functional abnormalities in T1D-derived FOXP3+Treg compared to healthy individuals [17]. 
In addition to defects in IL-2-mediated FOXP3+Treg maintenance, Teff in T1D patients are 
less sensitive to suppression by FOXP3+Treg [18]. A recent study by our group has shown 
that β cell-specific IL-2 delivery leads to tissue-specific expansion of a qualitatively distinct 
pool of Foxp3+Treg and suppression of the diabetogenic response in NOD mice [19]. The in 
vivo effects of IL-2 on human FOXP3+Treg, however, are ill-defined. 
Recent advances in humanized mice have allowed for the ability to study in vivo the 
effects of immunotherapies on human T cells without the restrictions associated with human 
clinical studies [20]. Injection of hematopoietic stem cells (HSC), and/or implantation of fetal 
bone marrow, liver, and thymic tissue (BLT) into immunodeficient mice, such as 
NOD.RagnullIL2rγnull (NRG) mice, results in development of a complete human immune 
system.  Injection of NRG mice with human PBMC (hu-PBL-NRG) is also an effective 
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approach to reconstitute the human T cell compartment in a murine host. hu-PBL-NRG mice 
have been used to study human T cell alloreactivity, and efficacy of human T cell-based 
therapies in vivo. Although no humanized mouse model generated to date has been able to 
model the spontaneous autoimmune destruction of β cells seen in T1D, PBMC derived from 
T1D patients can be used to successfully engraft diabetogenic T cells in hu-PBL-NRG mice 
[21].  
Low dose IL-2 therapy in humans has been used to treat a variety of T cell-mediated 
disorders such graft versus host disease (GvHD) and cancer [4]. However, due to the impact 
of IL-2 on a variety of immune cells and the difficulty associated with balancing doses to 
preferentially induce FOXP3+Treg without expanding Teff, low dose IL-2 therapy in the 
clinic has been problematic [22]. With the latter in mind, we used AAV vector-mediated 
gene delivery to localize human IL-2 expression in β cells of hu-PBL-NRG mice engrafted 
with CD4+ and CD8+ T cells derived from T1D or non-diabetic (ND) subjects. In general, 
AAV vectors are appealing for clinical use since: i) AAV vector DNA is non-integrating, ii) 
transgene expression can be detected long-term in vivo, iii) multiple capsid proteins are 
available for packaging to preferentially target tissues, and iv) packaged recombinants exhibit 
reduced immunogenicity relative to other viral-based vectors [23]. In the current study, we 
show that ectopic human IL-2 increases locally the frequency and number of T1D and ND-
derived FOXP3+Treg, marked by enhanced suppressor activity. 
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3.3 Material and Methods  
3.3.1 Mice 
NOD.Cg-Rag1tm1MomIl2rγtm1Wjl/SzJ (NRG) mice were bred and maintained in a 
specific pathogen-free facility in an American Association for Laboratory accredited animal 
facility. All procedures were approved by the University of North Carolina Institutional 
Animal Use and Care Committee.  
3.3.2 PBMC isolation and engraftment 
All protocols involving use and collection of PBMCs from T1D and healthy 
donors were in accordance with UNC-CH IRB guidelines. NRG mice were 
reconstituted with 15-20 x 106 fresh PBMC collected in heparin tubes and purified 
[24] using Ficoll-Paque Plus density gradient as per manufacturer’s instructions (GE 
Healthcare). Reconstitution of animals with human cells was monitored via flow 
cytometry for human CD45+ cells in peripheral blood. Experiments reached an end-
point at the onset of xenogeneic (x)GvHD monitored by weight loss (e.g. 15% of 
initial body weight).  
3.3.3 AAV vector engineering, packaging, and vaccination 
Full-length cDNA encoding human Il2 or EGFP were subcloned into a double 
stranded AAV plasmid [25] containing the murine insulin promoter (mIP), and packaged 
with AAV capsid serotype 8 as previously described [26]. Briefly, HEK 293T cells were 
transfected via polyethylamine with AAV capsid serotype 8, adeno helper plasmid (pXX6-
80), and double stranded plasmid containing mIP-driven IL-2. 72 h later nuclear fractions 
were collected, AAV vector purified using a cesium chloride density gradient, and titer 
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determined via Southern dot blot or qPCR. Mice were vaccinated with AAV8mIP-hIL2 or 
AAV8mIP-GFP via i.p. injection. 
3.3.4 Human islets 
Human islets isolated from deceased non-diabetic organ-donors were received 
through the Integrated Islet Distribution Program. Islet purity measured by dithizone was 
>92% for all donors. Islets were cultured at a density of 500 islet equivalent (IEQ)/mL in 
CMRL 1066 media containing 5mmol/l glucose at 37°C for the duration of the experiment.  
3.3.5 Flow cytometry 
Single cell suspensions were incubated with fluorescently conjugated monoclonal 
antibodies specific for CD45, CD3, CD4, CD8, CD25, and CD127. Fc receptors were 
blocked with anti-Fcγ 2.4G2 (BD Biosciences). Intracellular staining for FOXP3 and CTLA-
4 was performed following fixation and permeabilization using Fix/Perm and Perm/Wash 
(eBioscience) according to manufacturer’s instructions. 
3.3.6 ELISA  
Cell culture supernatants and sera collected from hu-PBL-NRG mice vaccinated with 
AAV vectors were assayed for human IL-2 in duplicate using an ELISA kit (BD 
Biosciences) as per manufacturer’s instructions.  
3.3.7 In vitro suppression assay  
Single cell suspensions prepared from hu-PBL-NRG mice vaccinated with 
AAV8mIP-GFP or AAV8mIP-hIL2 were used to enrich for CD4+CD25+CD127dim/- (Treg) 
and CD4+CD25- cells using Regulatory T cell Isolation Kit II (Milltenyi Biotec) as per 
manufacturer’s instructions. Cells were stimulated with anti-biotin particles prepared with 
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biotinylated antibodies against human CD2, CD3, and CD28 to mimic APCs at a ratio of 1:1 
(beads:T cell) using human T cell activation/expansion kit (Milltenyi Biotec) as per 
manufacturer’s instructions. CD4+CD25- T cells (responder) were labeled with Cell Trace 
Violet (CTV; Invitrogen); cell purity was >95% as determined by flow cytometry. Responder 
cells were plated at 100,000 cells per well and FOXP3+Treg titrated at varying ratios in 
complete RPMI media. Proliferation was measured 4 d later via dilution of CTV assessed by 
flow cytometry. 
3.3.8 Statistical analysis 
Graphpad Prism software was used to perform all statistical analyses. Unless 
otherwise indicated, statistical significance was calculated using Student’s t test.  
3.4 Results 
3.4.1 Ectopic human IL-2 expression increases pancreatic FOXP3+Treg 
NRG mice injected with human PBMC from ND and T1D donors were readily 
engrafted with human CD4+ and CD8+ T cells. The majority of human CD45+ cells in 
peripheral blood of hu-PBL-NRG mice were CD3+ T cells, which increased over time (Fig. 
3.1A). The ratio of CD4+:CD8+ T cells in the blood 5 wk following PBMC injection was 
approximately 1:1 (Fig. 3.1B). Similarly, CD3+ T cells were observed in the spleen, as well 
as the liver, and pancreas 5 wk following PBMC injection (Fig. 3.1C). T cell infiltration of a 
variety of tissues was due to the development of xGvHD, which was also reflected by a 
progressive loss of body weight (Fig. 3.1D). As expected, human T cells were not detected in 
lymph nodes, such as pancreatic and mesenteric lymph nodes (data not shown).  
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To test the effects of ectopic IL-2 on FOXP3+Treg and human conventional CD4+ and 
CD8+ T cells infiltrating the pancreas, an insulin promoter-driven human IL-2 AAV vector, 
packaged with pancreas-tropic capsid serotype 8 protein (AAV8mIP-hIL2) to target β cells, 
was prepared. To confirm expression of the IL-2 transgene, human islets were transduced in 
vitro with different doses of vector particles (v.p.) of AAV8mIP-hIL2, and human IL-2 levels 
measured in culture supernatants via ELISA. An AAV8mIP-hIL2 dose-dependent increase in 
human IL-2 was detected (Fig. 3.2A) demonstrating that the vector was functional.  
Three weeks post-transfer of ND PBMC, hu-PBL-NRG mice were injected i.p. with 
2.5x1010 v.p. of AAV8mIP-hIL2, and peripheral blood T cells examined. FOXP3+Treg were 
defined as CD4+CD25+CD127low whereas conventional CD4+ and CD8+ T cells were 
identified based expression of CD3 among live human CD45+ cells. AAV8mIP-hIL2 had no 
marked effect on the frequency or number of peripheral blood CD3+CD4+ (Fig. 3.2B) or 
CD3+CD8+ (Fig. 3.2C) T cells relative to untreated hu-PBL-NRG mice. Alternatively, 2 wk 
following injection of AAV8mIP-hIL2 the frequency (Fig. 3.2D) and number of 
FOXP3+Treg, were increased up to 2-fold and 4-fold in peripheral blood of hu-PBL-NRG 
mice, respectively (Fig. 3.2E). Expression of CTLA-4 by FOXP3+Treg in the periphery was 
unaffected by AAV8mIP-hIL-2 treatment (Fig. 3.2F).  
Analysis of the pancreas of hu-PBL-NRG mice 2 wk post-AAV8 vector injection 
showed that the frequency (Fig. 3.3A) and number (Fig. 3.3B) of FOXP3+Treg were 
increased by AAV8mIP-hIL2 versus AAV8mIP-GFP on average ~3-fold, and up to 8-fold 
depending on the ND donor. Increased frequency and number of FOXP3+Treg was not 
restricted to the pancreas. In some instances FOXP3+Treg were also increased in the spleen 
and liver of AAV8mIP-hIL2-treated hu-PBL-NRG mice established with certain donors (Fig. 
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3.3A, B). This is not unexpected because IL-2 produced by β cells is secreted into the blood. 
However, the robust preferential increase in the pancreas suggests that FOXP3+Treg 
expansion is largely tissue-specific. In humans, CD25 expression among CD4+ T cells is not 
limited to the suppressive FOXP3+Treg pool since conventional T cells can also express 
intermediate to high levels of CD25 and FOXP3 upon activation [15]. Splenic, liver, and 
pancreatic FOXP3+Treg showed similar levels of CD25 expression (Fig. 3.3C).  
To determine whether ectopic human IL-2 expression affected FOXP3+Treg function, 
an in vitro suppressor assay was carried out. Splenic FOXP3+Treg were isolated from hu-
PBL-NRG mice treated with AAV8mIP-hIL2 or AAV8mIP-GFP and suppression of CTV-
labeled CD4+CD25- T cell proliferation stimulated with human CD2, CD3, and CD28 
specific antibodies determined. FOXP3+Treg isolated from AAV8mIP-hIL2 vaccinated hu-
PBL-NRG animals were markedly better at suppressing CD4+ T cell proliferation compared 
to suppressive capability of FOXP3+Treg from AAV8mIP-GFP treated animals (Fig. 3.3D). 
3.4.2 AAV8mIP-hIL2 administration has no effect on conventional T cell pool 
To determine whether ectopic IL-2 expression affected conventional T cells, 
frequency and number of CD4+ (Fig. 3.4A, C) and CD8+ (Fig. 3.4B, D) T cells in spleen, 
liver, and pancreas of hu-PBL-NRG were determined. Frequency and number of 
conventional T cells remain unchanged following AAV8mIP-hIL2 treatment compared to 
AAV8mIP-GFP treated controls. In some cases, i.e. ND1 and ND3, we observed a reduction 
in number of conventional CD4+ T cells following AA8mIP-hIL2 treatment in pancreas 
(ND1) and spleen (ND3) (Fig. 3.4A). These data suggest that ectopic human IL-2 affects 
FOXP3+Treg without exerting any effects on conventional T cells.  
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3.4.3 FOXP3+Treg in T1D-derived PBMC hu-PBL-NRG mice are increased following 
AAV8mIP-hIL2 treatment 
To investigate whether FOXP3+Treg in T1D hu-PBL-NRG mice were responsive to 
AAV8mIP-hIL2 treatment, T1D PBMC were injected into NRG mice and 3 wk later were 
treated with AAV8mIP-hIL2 or AAV8mIP-GFP. Engraftment kinetics and frequencies of 
CD3+, CD4+, and CD8+ T cells in peripheral blood of T1D huPBL-NRG mice were similar to 
ND hu-PBL-NRG mice (data not shown). Frequency of splenic, liver, and pancreatic 
FOXP3+Treg exhibited a modest 1.5-2-fold increase in hu-PBL-NRG derived from 1 of 2 
T1D PBMC donor following AAV8mIP-hIL2 compared to control treated cohorts (Fig. 
3.5A). Consistent with increased FOXP3+Treg frequency, the numbers of splenic and 
pancreatic FOXP3+Treg were increased 8-fold and 2.5-fold, respectively (Fig. 3.5B). These 
preliminary data suggest that T1D-derived FOXP3+Treg are induced following ectopic IL-2 
expression.  
Furthermore, AAV8mIP-hIL2 treatment had no effect on frequency and number of 
conventional CD4+ (Fig. 3.6A, C) and CD8+ (Fig. 3.6B, D) T cell in spleen, liver, and 
pancreas of T1D hu-PBL-NRG mice compared to AAV8mIP-GFP control treated mice. 
These data demonstrate that AAV8mIP-hIL2 treatment affects FOXP3+Treg and Tconv in 
T1D hu-PBL-NRG mice comparably to results obtained with ND hu-PBL-NRG mice. 
3.5 Discussion 
The progression of human T1D is in part associated with impaired maintenance 
and/or function of FOXP3+Treg, and the resistance to suppression of Teff. In human and in 
NOD mice, defects in FOXP3+Treg function, survival, and maintenance have been associated 
with development of diabetes [27]. Recent studies by our group and others using NOD mice 
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have shown that reduced levels of IL-2 results in diminished survival of islet-infiltrating 
Foxp3+Treg [28-30]. Consequently, pathogenic Teff readily expand and drive β cell 
destruction. On the other hand, systemic delivery of “low-dose” IL-2 prevents diabetes in 
NOD mice by enhancing the survival and numbers of islet-infiltrating Foxp3+Treg [29, 31]. 
A recently published report by our group showed that β cell-specific expression of IL-2 
suppresses T1D development in NOD mice by expanding local pool of islet Foxp3+Treg and 
reducing islet-resident Teff [19]. Notably, in vitro studies have demonstrated that 
FOXP3+Treg from T1D patients exhibit an impaired response to IL-2 that reduces survival 
and function [18]. Our results suggest that β cell specific human IL-2 expression is able to 
induce expansion of FOXP3+Treg in hu-PBL-NRG mice derived from both T1D and ND 
PBMCs, though we need to further investigate the responsiveness of FOXP3+Treg to ectopic 
IL-2 in T1D derived hu-PBL-NRG.  
Using AAV vectors to deliver human IL-2 in NRG mice reconstituted with human 
PBMC, we found that human FOXP3+Treg are expanded in the pancreas of hu-PBL-NRG 
mice derived from both T1D and ND PBMC (Fig. 3.3 and 3.5). Coupled with no alteration in 
the CD4+ and CD8+ T cell pool (Fig. 3.4 and 3.6), these results suggest that ectopic human 
IL-2 expression is sufficient to markedly increase the FOXP3+Treg pool. Effects of human 
IL-2 on CD4+ and FoxP3+T cells may be distinct in hu-PBL-NRG mice. These differential 
effects might be explained by level of IL-2R signaling. IL-2/IL-2R interaction leads to 
downstream phosphorylation of STAT5 molecule. What effects human IL-2 has on IL-2R 
signaling and on Teff, however, needs to be studied in further detail. Importantly, it remains 
to be determined whether expanded FOXP3+Treg following ectopic IL-2 expression is due to 
increased survival and/or proliferation. Similarly, proliferation, survival, and apoptosis of 
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Teff might also be affected. In accordance with previously reported studies, we observed 
engrafted T cells in hu-PBL-NRG mice to be highly activated [32]. Moreover, it is currently 
unknown whether engrafted T cells in the organs of hu-PBL-NRG mice display a phenotype 
characteristic of exhaustion and further examination for expression of PD-1 and CD244, 
markers of human T cell exhaustion, needs to be performed.  
A notable aspect of the expanded FOXP3+Treg pool in AAV8mIP-hIL2-treated mice 
was the increase in “fitness”. Following incubation with CD4+FOXP3- T cells, 
CD4+CD25+CD127-FOXP3+Treg exhibited up to a 1.5-fold increase in suppressive 
capability (Fig. 3.3D). Whether ectopic human IL-2 expression induces a qualitatively 
distinct pool of FOXP3+Treg however remains to be determined. Human FOXP3+Treg are 
functionally and phenotypically diverse, and whether ectopic human IL-2 can promote 
expansion of specific FOXP3+Treg subsets in vivo is an interesting possibility that needs 
investigation. Unlike murine Foxp3+Treg, all human FOXP3-expressing Treg are not 
regulatory in function. In fact, based on surface expression of CD45RO and CD45RA, 
FOXP3+Treg can be reclassified into highly suppressive and hypo-suppressive groups [11, 
15]. Suppressive phenotype of FOXP3+Treg can also be determined by analyzing expression 
of CTLA-4 and GITR in FOXP3+Treg following AAV8mIP-hIL2 treatment. Additionally, 
analyses to identify CD62L- and CCR4-expressing FOXP3+Treg need to be conducted, as 
well as characterization of CD45RO+ memory/effector and CD45RA+ naïve phenotypes [33, 
34]. 
A key aspect of our study was to determine whether ectopic human IL-2 expression 
induces expansion of FOXP3+Treg in hu-PBL-NRG mice derived from T1D PBMC. Our 
data suggests that this is indeed the case, and we observed an increased number and a modest 
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increase in frequency of FOXP3+Treg in organs of T1D hu-PBL-NRG mice following 
treatment with AAV8mIP-hIL2 (Fig. 3.5A,B). Notably, this is the first study to assess the 
ability of FOXP3+Treg to expand in response to ectopic human IL-2 in a T1D PBMC-derived 
hu-PBL-NRG mouse model. Previous studies have reported that although frequency of 
FOXP3+Treg present in peripheral blood of T1D individuals is similar to that found in ND 
individuals, their ability to suppress Teff is defective [17, 33, 35]. It is currently unclear, 
however, whether the expanded pool of FOXP3+Treg in AAV8mIP-hIL2 vaccinated T1D hu-
PBL-NRG mice will demonstrate enhanced suppressive capability and this possibility, as 
well as determining the functional phenotype of FOXP3+Treg induced in T1D hu-PBL-NRG 
animals, is the goal of ongoing studies. Taken together, these results will help us further 
understand the mechanisms associated with impaired FOXP3+Treg regulation in T1D 
individuals and how best to employ immunotherapies targeting FOXP3+Treg to circumvent 
impaired Treg “fitness”. We have previously shown the efficacy of using AAV vectors to 
mediate cytokine expression long-term and without adverse immune effects [19]. Here our 
study provides further evidence that AAV vectors are highly desirable in specifically 
targeting FOXP3+Treg, which are the prime mediators of suppressing autoimmunity in both 
humans and mouse.  
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Figure 3.1: Engraftment of human T cells in hu-PBL-NRG mice. Groups of 4-8 10-12 wk 
old NRG mice were injected i.p. with 15-20x106 PBMC from ND donors. CD3+ T cells in 
peripheral blood (A), and spleen, liver, and pancreas 5 wk later (C) were assessed by flow 
cytometry. (B) Frequency of live CD45-gated CD3+CD4+ and CD3+CD8+ T cells in 
peripheral blood was assessed. (D) Development of xGvHD in hu-PBL-NRG mice measured 
by average body weight of animals following PBMC injection.
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Figure 3.2: Expression of human IL-2 and analyses of human T cells in ND-derived hu-
PBL-NRG mice treated with AAV8mIP-hIL2. (A) Human IL-2 levels were measured in 
supernatants from human islets derived from ND donors transduced with AAV8mIP-hIL2 or 
left untreated. Data are representative of two independent experiments. ****p<0.0001, 
**p<0.01, *p<0.05 (Student’s t test) ±SEM. Frequency and number of live CD45-gated 
CD3+, CD4+ (B) or CD8+ T cells (C) was measured in AAV8mIP-hIL2 and AAV8mIP-GFP 
treated cohorts. FOXP3+Treg frequency among CD4+ pool (D) and number (E) was 
measured in peripheral blood of hu-PBL-NRG mice 2 wk following treatment with 
AAV8mIP-hIL2 (n=3). (F) CTLA-4 expression among peripheral blood FOXP3+Treg was 
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determined 2 wk following treatment with AAV8mIP-hIL2 compared to untreated control 
hu-PBL-NRG mice. *p<0.05 (Student’s t test) ±SEM.   
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Figure 3.3: Ectopic human IL-2 expression increases the frequency and number of 
FOXP3+Treg. Frequency (A), number (B), and level of expression of CD25 (C) of human 
CD45+CD3+CD25+CD127-FoxP3+ T cells were assessed in spleen, liver, and pancreas of hu-
PBL-NRG mice vaccinated with AAV8mIP-GFP or AAV8mIP-hIL2 2 wk post-treatment. 
Unfilled and filled circles each represent 3-6 mice per group. (D) In vitro suppressor activity 
of splenic Treg (CD4+CD25+CD127dim/-) enriched from mice vaccinated with AAV8mIP-
GFP or AAV8mIP-hIL2 was assessed via flow cytometry. ****p<0.0001, **<0.01, *p<0.05 
(Student’s t test) ±SEM. 
  
A
B 
C 
1 2 3 4 5 6 7 8 9 10 11
0
2
4
6
10
20
30
40
Nondiabetic Donor
%
Sp
l F
O
XP
3+
Tr
eg
AAV8mIP-GFP
AAV8mIP-hIL2
*
1 2 3 4 5 6 7 8 9 10 11
0
5
10
15
Nondiabetic Donor
%
Li
ve
r F
O
XP
3+
Tr
eg AAV8mIP-GFP
AAV8mIP-hIL2
*
*
1 2 3 4 5 6 7 8 9 10 11
0
2
4
6
10
20
30
40
Nondiabetic Donor
%
Pa
n 
FO
XP
3+
Tr
eg
AAV8mIP-GFP
AAV8mIP-hIL2
*
*
*
**
**
* *
****
1 2 3 4 5
0
1×105
2×105
3×105
5.0×105
1.0×106
1.5×106
Nondiabetic Donor
N
o.
 o
f s
pl
 F
O
XP
3+
Tr
eg AAV8mIP-GFP
AAV8mIP-hIL2
1 2 3 4 5 6
0
500
1,000
5,000
10,000
20,000
40,000
Nondiabetic Donor
N
o.
 o
f p
an
 F
O
XP
3+
Tr
eg AAV8mIP-GFP
AAV8mIP-hIL2
*
0
100
200
300
1000
2000
1 2 3 4 5
C
D
25
 M
FI
 in
 s
pl AAV8mIP-GFP
Nondiabetic Donor
AAV8mIP-hIL2
1 2 3 4 5
0
500
1000
1500
2000
Nondiabetic Donor
C
D
25
 M
FI
 in
 li
ve
r
AAV8mIP-GFP
AAV8mIP-hIL2
1 2 3 4 5 6
0
100
200
500
1000
1500
2000
Nondiabetic Donor
C
D
25
 M
FI
 in
 p
an
AAV8mIP-GFP
AAV8mIP-hIL2
1:1 1:2
0
20
40
60
80
100
Treg to CD4+ T cell ratio
%
Pr
ol
ife
ra
te
d
AAV8mIP-GFP
AAV8mIP-hIL2
**
*
D 
  87 
 
 
Figure 3.4: Ectopic human IL-2 has no effect on the number of conventional T cells in 
hu-PBL-NRG mice. Number of live CD45+CD3+-gated CD4+ (A) and CD8+ (B) T cells was 
determined in the spleen and pancreas of AAV8mIP-GFP or AAV8mIP-hIL2-treated hu-
PBL-NRG mice. Frequency of CD4+ (C) and CD8+ (D) T cells in the spleen, liver, and 
pancreas determined.  Unfilled and filled circles each represent 2-6 mice per group. 
**p<0.01, *p<0.05 (Student’s t test) ±SEM. 
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Figure 3.5: AAV8mIP-hIL2 treatment increases frequency and number of FOXP3+Treg 
in T1D hu-PBL-NRG mice. Groups of 3-4 T1D PBMC-derived hu-PBL-NRG mice were 
treated with AAV8mIP-GFP or AAV8mIP-hIL2. 2 wk later live CD45+CD3+ were gated on 
and frequency (A) and number (B) of FOXP3+Treg determined. *p<0.05 (Student’s t test) 
±SEM. 
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Figure 3.6: Conventional T cell numbers remain unchanged in T1D hu-PBL-NRG mice 
following AAV8mIP-IL2 treatment. Groups of 3-4 T1D hu-PBL-NRG mice treated with 
AAV8mIP-GFP or AAV8mIP-hIL2 and 2 wk later live CD45+CD3+-gated CD4+ (A) and 
CD8+ T cell (B) were determined in spleen, liver, and pancreas via flow cytometry. Number 
of CD4+ (C) and CD8+ (D) T cells were determined in spleen and pancreas of AAV8mIP-
GFP or AAV8mIP-hIL2 treated hu-PBL-NRG mice. 
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CHAPTER 4: DISCUSSION 
Immunotherapy in T1D falls under two categories: targeted and broad-based 
approaches. Targeted approaches include antigen-specific therapy in which β cell-specific 
autoantigens such as insulin or GAD65 are administered to selectively manipulate the 
diabetogenic T cell pool [1-4]. On the other hand, broad-based therapies such as anti-CD3 Ab 
target Teff associated with autoimmunity as well as normal protective immunity [1-4]. AAV 
based immunotherapy for T1D is promising because it allows delivery to and expression of 
transgenes directly to β cells, thereby limiting unwanted systemic complications [1, 5-9]. 
Additionally AAV-mediated immunotherapy establishes stable, long-term transgene 
expression with limited need for re-administration [10]. In this dissertation, AAV-based 
immunotherapy was used to investigate: i) the efficacy of IL-35 to suppress ongoing β cell 
autoimmunity and prevent the onset of clinical diabetes, and ii) the qualitative and 
quantitative effects of ectopic IL-2 on T1D- and ND-derived pancreatic human Teff and 
FOXP3+Treg.  
In our first study, we showed that ectopic IL-35 expression was sufficient to reduce 
the number and suppress proliferation of T cells in the islets of NOD mice, and that this was 
independent of differentiation of Tr35 cells (Chapter 2). Studies have shown that naïve T 
cells upon antigen-stimulation in the presence of TGFβ or IL-10 differentiate into 
suppressive TGFβ-secreting Th3 and IL-10-secreting Tr1 cells, respectively. Similarly, in the 
presence of IL-35, both human and mouse naïve CD4+FoxP3- T cells differentiate into an IL-
35-secreting Tr35 suppressive population [11]. These Tr35 cells neither require nor express 
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FoxP3, and suppress Tconv in a cytokine-dependent, and contact-independent manner [11]. 
Studies have shown that Tr35 cells are more potent at inhibiting T cell proliferation and 
effector function than other induced Treg populations, such as Tr1 and Th3 cells [12]. 
Unfortunately, due to lack of resources available to directly detect Tr35 in vivo, i.e. no 
known cell-surface marker unique to Tr35 cells, and lack of a commercially available 
antibody to detect IL-35 protein levels, it is challenging to track Tr35 cell function in vivo. 
As of yet, the role of endogenous IL-35 and Tr35 cells in the islet inflammatory environment 
is unknown. Additionally, the stability of Tr35 cells in vivo is unknown, especially in the 
islets of NOD mice. It is possible that permanent conversion of Tr35 cells in vivo requires 
constant secretion of IL-35 by Foxp3+Treg, which is induced upon contact of Foxp3+Treg 
with Tconv. IL-35 expression by Foxp3+Treg, however, is not constitutive and likely 
depends on the inflammatory environment in which Foxp3+Treg are present. Our data, 
coupled with previous observations, suggest a defect in local islet IL-35 production in NOD 
mice that could contribute to T1D [13]. Elucidating mechanisms regulating development of 
Tr35 cells can shed light on to the role of these cells in T1D as well as other autoimmune and 
inflammatory diseases.  
Foxp3+Treg are the primary producers of IL-35, and co-culture with Foxp3+Treg is 
sufficient to induce Tconv differentiation into Tr35 cells, which are characterized by 
upregulation of IL-12a and Ebi3 genes [11, 14]. The mechanisms regulating IL-35 secretion 
by Treg, however, remain elusive. It is not yet known whether a pro-inflammatory response, 
non-specific TCR engagement, or activation of antigen-specific Foxp3+Treg lead to IL-35 
production in vivo. Studies utilizing neutralizing antibodies (nAb) against IL-10, IL-35, and 
TGFβ found that while TGFβ was dispensable, IL-10 was needed along with IL-35 for 
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optimal Tr35 differentiation [11]. In our studies, levels of IL-10 in the islet environment were 
relatively low, which would be expected to limit Tr35 cell differentiation despite the 
presence of IL-35. Although the IL-12a and Ebi3 gene signature was absent from islet 
Thy1.2+FoxP3- cells in our studies, this result alone is not sufficient to rule out development 
of Tr35 cells in vivo. Generation of a significant pool of Tr35 cells in the islets might benefit 
from increased IL-10 expression. This can be readily achieved by administering both 
AAV8mIP-IL-35 and a β cell-specific IL-10 (AAV8mIP-IL10) recombinant. Using this 
approach, the role of Tr35 cells in regulating β cell autoimmunity and preventing diabetes 
onset can be directly investigated. Furthermore, the combination of AAV vector-mediated 
IL-35 and IL-10 expression can be used to prevent rejection of in vitro transduced islet 
allografts.  
One caveat with using AAV vectors is the potential of pre-existing and/or induction 
of nAb specific for the capsid proteins that in turn interfere with transduction in vivo. AAV 
isolates from humans and other species are designated as distinct serotypes based on a lack of 
cross-reactivity with other AAV serotypes [15, 16]. In fact, studies have shown that 
vaccination with two distinct serotypes has no effect on transduction efficiency or transgene 
expression. However, nAb specific for a particular AAV capsid serotype are found 
circulating as early as 3 days post-vaccination [17]. Humoral responses to AAV present a 
challenge for using AAV vectors for gene therapy, especially if re-vaccination is required. 
Ongoing studies to determine nAb binding sites on AAV capsids and using mutagenesis to 
engineer capsids to generate new variants that can preclude anti-AAV response are promising 
[18].  
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The progression of human T1D in mouse and human is associated with impaired 
maintenance and/or function of FOXP3+Treg, and expansion of Teff that are resistant to 
FOXP3+Treg-mediated suppression.  In our second study, hu-PBL-NRG mice engrafted with 
T1D and ND CD4+ and CD8+ T cells were used to define defects associated with T1D-
derived FOXP3+Treg and Teff, as well as to determine if IL-2 is sufficient to override these 
defects. We demonstrated that ectopic human IL-2 expression expands human FOXP3+Treg 
in both T1D and ND-derived hu-PBL-NRG mice (Chapter 3). Further investigation is 
necessary, however, to better delineate effects of ectopic IL-2 expression on human Teff. 
Preliminary data utilizing NSG-BLT mice, which develop a more complete human immune 
system, also showed significant expansion of pancreatic FOXP3+Treg following AAV8mIP-
hIL2 treatment, providing further support for the use of AAV8mIP-hIL2 therapy to induce a 
tissue-specific increase in FOXP3+Treg.  
Based on results obtained using AAV8mIP-hIL2 therapy, it is worth investigating 
whether expanded FOXP3+Treg are sufficient to block allograft rejection in vivo. Successful 
β cell replacement represents a cure for T1D, and islet allograft transplantation may provide 
a long-term solution [19]. Unfortunately, the therapeutic effect of islet allograft 
transplantation in T1D patients is only transient, lasting no more than 5 years at most [19, 
20]. Islet allograft survival is most likely diminished by a variety of factors, including 
allogeneic reactivity, persistent anti-islet autoimmunity, the quality and integrity of 
transplanted islets, as well as deleterious effects of immunosuppressive drugs on the viability 
and function of the transplanted β cells. Being able to study human islet allograft survival 
and function in humanized mice presents an unique opportunity to understand the mechanism 
of allograft rejection and aid in developing strategies to prevent and/or delay rejection. 
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Human and mouse islet allografts are able to establish euglycemia in STZ-induced diabetic 
NRG mice, as well as in spontaneously diabetic NRG.InsAkita mice [21, 22]. PBMC 
engraftment in mice implanted with islet grafts leads to allograft rejection within 30 days. 
Although use of hu-PBL-NRG mouse model is adequate for transplantation studies due to 
robust reconstitution of human T cells in these mice, the NSG-BLT model is a better model 
since it is more reflective of physiological conditions e.g. a large pool of un-activated T cells. 
CD4+ and CD8+ T cells, in particular, drive graft rejection of target tissue in vivo. A recent 
study showed that injection of human FOXP3+Treg in NSG mice reconstituted with HSC 
(hu-HSC-NSG) and implanted with human islet allograft significantly delayed islet allograft 
rejection [23]. Local expansion of FOXP3+Treg in islet allografts following ectopic IL-2 
expression, or suppression of Teff responses by ectopic human IL-35 expression may block 
or significantly delay graft rejection.  
A variety of Treg subsets can be found at sites of autoimmunity or allograft rejection, 
each with distinct immunoregulatory mechanisms. AAV vectors encoding different cytokines 
such as IL-10, IL-35 or TGFβ can be exploited to manipulate Treg in a tissue-specific 
manner for the purpose of immunotherapy, as well as to define the role of the respective Treg 
in suppressing ongoing inflammation. Our studies further underscore the value of this 
strategy.       
  99 
4.1 REFERENCES 
1 Han, G., Wang, R., Chen, G., Wang, J., Xu, R., Feng, J., Yu, M., Wu, X., Qian, 
J., Shen, B. and Li, Y., Gene delivery GAD 500 autoantigen by AAV serotype 1 
prevented diabetes in NOD mice: transduction efficiency do not play important roles. 
Immunol Lett 2008. 115: 110-116. 
2 Ludvigsson, J., Faresjo, M., Hjorth, M., Axelsson, S., Cheramy, M., Pihl, M., 
Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., Lindh, A., Nilsson, N. 
O., Aman, J., Ortqvist, E., Zerhouni, P. and Casas, R., GAD treatment and insulin 
secretion in recent-onset type 1 diabetes. N Engl J Med 2008. 359: 1909-1920. 
3 Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, 
L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., Schandene, L., 
Crenier, L., De Block, C., Seigneurin, J. M., De Pauw, P., Pierard, D., Weets, I., 
Rebello, P., Bird, P., Berrie, E., Frewin, M., Waldmann, H., Bach, J. F., 
Pipeleers, D. and Chatenoud, L., Insulin needs after CD3-antibody therapy in new-
onset type 1 diabetes. N Engl J Med 2005. 352: 2598-2608. 
4 Waldron-Lynch, F., Henegariu, O., Deng, S., Preston-Hurlburt, P., Tooley, J., 
Flavell, R. and Herold, K. C., Teplizumab induces human gut-tropic regulatory cells 
in humanized mice and patients. Sci Transl Med 2012. 4: 118ra112. 
5 Goudy, K. S., Johnson, M. C., Garland, A., Li, C., Samulski, R. J., Wang, B. and 
Tisch, R., Inducible adeno-associated virus-mediated IL-2 gene therapy prevents 
autoimmune diabetes. J Immunol 2011. 186: 3779-3786. 
6 Johnson, M. C., Garland, A. L., Nicolson, S. C., Li, C., Samulski, R. J., Wang, B. 
and Tisch, R., beta-cell-specific IL-2 therapy increases islet Foxp3+Treg and 
suppresses type 1 diabetes in NOD mice. Diabetes 2013. 62: 3775-3784. 
7 Rehman, K. K., Trucco, M., Wang, Z., Xiao, X. and Robbins, P. D., AAV8-
mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of 
diabetes in NOD mice. Mol Ther 2008. 16: 1409-1416. 
8 Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, 
V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., Couto, L. B., Leonard, 
D. G., Johnson, F. A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A. W., 
Kay, M. A., High, K. A. and Glader, B., AAV-mediated factor IX gene transfer to 
skeletal muscle in patients with severe hemophilia B. Blood 2003. 101: 2963-2972. 
9 Riedel, M. J., Gaddy, D. F., Asadi, A., Robbins, P. D. and Kieffer, T. J., 
DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells 
ameliorates streptozotocin-induced diabetes. Gene Ther 2010. 17: 171-180. 
10 Asokan, A., Schaffer, D. V. and Samulski, R. J., The AAV vector toolkit: poised at 
the clinical crossroads. Mol Ther 2012. 20: 699-708. 
  100 
11 Collison, L. W., Chaturvedi, V., Henderson, A. L., Giacomin, P. R., Guy, C., 
Bankoti, J., Finkelstein, D., Forbes, K., Workman, C. J., Brown, S. A., Rehg, J. 
E., Jones, M. L., Ni, H. T., Artis, D., Turk, M. J. and Vignali, D. A., IL-35-
mediated induction of a potent regulatory T cell population. Nat Immunol 2010. 11: 
1093-1101. 
12 Olson, B. M., Sullivan, J. A. and Burlingham, W. J., Interleukin 35: a key mediator 
of suppression and the propagation of infectious tolerance. Front Immunol 2013. 4: 
315. 
13 Bettini, M., Castellaw, A. H., Lennon, G. P., Burton, A. R. and Vignali, D. A., 
Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of 
interleukin-35. Diabetes 2012. 61: 1519-1526. 
14 Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., 
Cross, R., Sehy, D., Blumberg, R. S. and Vignali, D. A., The inhibitory cytokine 
IL-35 contributes to regulatory T-cell function. Nature 2007. 450: 566-569. 
15 Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., 
Weichert, W. S., Nelson, C. D., Chen, W. J., Muzyczka, N., Olson, N. H., 
Sinkovits, R. S., Chiorini, J. A., Zolotutkhin, S., Kozyreva, O. G., Samulski, R. 
J., Baker, T. S., Parrish, C. R. and Agbandje-McKenna, M., Capsid antibodies to 
different adeno-associated virus serotypes bind common regions. J Virol 2013. 87: 
9111-9124. 
16 Mingozzi, F. and High, K. A., Immune responses to AAV vectors: overcoming 
barriers to successful gene therapy. Blood 2013. 122: 23-36. 
17 Samulski, R. J. and Muzyczka, N., AAV-Mediated Gene Therapy for Research and 
Therapeutic Purposes. Annu Rev Virol 2014. 1: 427-451. 
18 Tseng, Y. S. and Agbandje-McKenna, M., Mapping the AAV Capsid Host 
Antibody Response toward the Development of Second Generation Gene Delivery 
Vectors. Front Immunol 2014. 5: 9. 
19 Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., 
Lakey, J. R. and Shapiro, A. M., Five-year follow-up after clinical islet 
transplantation. Diabetes 2005. 54: 2060-2069. 
20 Atkinson, M. A., Eisenbarth, G. S. and Michels, A. W., Type 1 diabetes. Lancet 
2014. 383: 69-82. 
21 Diiorio, P., Jurczyk, A., Yang, C., Racki, W. J., Brehm, M. A., Atkinson, M. A., 
Powers, A. C., Shultz, L. D., Greiner, D. L. and Bortell, R., Hyperglycemia-
induced proliferation of adult human beta cells engrafted into spontaneously diabetic 
immunodeficient NOD-Rag1null IL2rgammanull Ins2Akita mice. Pancreas 2011. 40: 
1147-1149. 
  101 
22 Brehm, M. A., Bortell, R., Diiorio, P., Leif, J., Laning, J., Cuthbert, A., Yang, C., 
Herlihy, M., Burzenski, L., Gott, B., Foreman, O., Powers, A. C., Greiner, D. L. 
and Shultz, L. D., Human immune system development and rejection of human islet 
allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice. 
Diabetes 2010. 59: 2265-2270. 
23 Xiao, F., Ma, L., Zhao, M., Huang, G., Mirenda, V., Dorling, A., Lechler, R. and 
Lombardi, G., Ex vivo expanded human regulatory T cells delay islet allograft 
rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production 
in CD34+ stem cells-reconstituted NOD-scid IL2rgammanull mice. PLoS One 2014. 
9: e90387. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  102 
APPENDIX 1: ISOLATION AND TRANSPLANTATION OF DIFFERENT 
AGED MURINE THYMIC GRAFTS2 
A1.1 Summary 
The mechanisms that regulate the efficacy of thymic selection remain ill-defined. The 
method presented here allows in vivo analyses of the development and selection of T cells 
specific for self and foreign antigens. The approach entails implantation of thymic grafts 
derived from various aged mice into immunodeficient scid recipients. Over a relatively short 
period of time the recipients are fully reconstituted with T cells derived from the implanted 
thymus graft. Only thymocytes seeding the thymus at the time of isolation undergo selection 
and develop into mature T cells. As such, changes in the nature and specificity of the 
engrafted T cells as a function of age-dependent thymic events can be assessed. Although 
technical expertise is required for successful thymic transplantation, this method provides a 
unique strategy to study in vivo a wide range of pathologies that are due to or a result of 
aberrant thymic function and/or homeostasis. 
A1.2 Introduction 
The thymus is an organ in which critical events in T cell development occur [1]. 
Resident thymocytes, upon rearrangement of the T cell receptor (TCR) a and b genes, 
undergo a series of interactions with lymphostromal and antigen presenting cells (APC) in 
the cortical and medullary regions of the thymus [2]. Thymic positive selection is mediated 
by cortical thymic epithelial cells (TEC) to produce thymocytes that recognize antigenic 
peptides in the context of host major histocompatibility complex (MHC) class I and II 
                                                            
 
2 This chapter has been previously published and represents a co-first author work. The original citation is as 
follows: Morillon II, Y. M., Manzoor, F., Wang, B., & Tisch, R. (2015). Isolation and transplantation of 
different aged murine thymic grafts. J Vis Exp, (99), e52709. doi:10.3791/52709. Video component of this 
article can be found at: http://www.jove.com/video/52709. 
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molecules [2, 3]. Subsequent thymic negative selection entails purging of autoreactive 
thymocytes, driven by an interaction with medullary TEC or dendritic cells (DC) that present 
peptides derived from self-proteins bound by MHC class I and II molecules [3]. The end 
result of these processes is the establishment of a pool of mature CD4+ and CD8+ T cells able 
to respond to a broad spectrum of foreign antigens while exhibiting minimal reactivity to 
self-proteins [4].  
The efficiency of thymic selection events is influenced by a host of factors, including 
thymic maturation, frequency of medullary and cortical TEC, subset composition of thymic 
DC, and the source of thymic precursors [3]. Notably, aberrant thymic selection can result in 
autoimmune or immunodeficient pathologies, which arise from impaired negative or positive 
selection, respectively [5]. The molecular events regulating thymic selection, however, are 
poorly understood. In vitro approaches such as reaggregate thymic organ cultures (RTOC), 
have proven to be useful for analyzing basic events associated with thymic selection, but fail 
to fully recapitulate the dynamics of ongoing in vivo events [6]. As a result, this thymic 
transplantation-based approach was established to better study thymocyte selection events in 
vivo [7].  
This protocol describes transplanting thymi from newborn and adult donor mice into 
immunodeficient scid recipient mice. This technique permits the study of mechanisms that 
regulate positive and negative thymic selection, as well as thymic output of various T cell 
subsets during ontogeny. Most recently, this approach has been used to demonstrate that the 
efficiency of thymic selection is limited early after birth in mice leading to increased 
development of autoreactive T cells, and a reduced T cell repertoire specific for foreign 
antigens [7]. 
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A1.3 Protocol  
The murine studies were approved by the Animal Care and Use Committee of the 
University of North Carolina Chapel Hill and all animal care was in accordance with the 
IACUC guidelines.  
A1.3.1. Preparation of Newborn and Adult Thymi 
1.1) Prepare all reagents and equipment prior to euthanizing donor mice.  
 
1.1.1) Sterilize surgical instruments by autoclaving or other appropriate methods. All surgical 
procedures must be performed under a laminar flow hood to maintain sterile conditions and 
avoid contamination. Assemble the tools needed for extraction of thymi from donor mice. 
 
1.2) Fill a 60 mm dish with sterile 1x PBS and place on ice inside the hood. This will be used 
to briefly store thymi excised from donor mice prior to transplantation. 
   
1.3) As per ethical guidelines, euthanize newborn donor mice by decapitation and adult 
donor mice by CO2 asphyxiation followed by cervical dislocation. For removal of the 
thymus: 
  
1.3.1) Lay the mouse in a dorsal recumbent position on a sterile absorbent paper towel and 
spray with 70% ethanol prior to making an incision.  
 
1.3.2) Expose the abdominal and thoracic cavity by making a midline incision through the 
skin. Fold the skin over the chest and forelimbs to reveal the thoracic cavity. 
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1.3.3) Make two lateral incisions through the diaphragm and ribcage to expose the superior 
mediastinum and anterior thoracic cavity. The thymus should be visible as two white lobes 
immediately above and adjacent to the heart.  
 
1.3.4) Tease apart the connective tissue surrounding the thymus with fine forceps, making 
certain not to disrupt the capsule. While holding back the ribcage with forceps, use a second 
pair of forceps to extract the two lobes of the thymus by positioning curved forceps 
underneath the organ and pulling vertically. This can be done using a dissecting scope for 
extracting thymi from newborn mice.  
 
1.4) Place the thymus in the 60 mm dish containing sterile 1x PBS (pH 7.4) on ice and 
separate thymic lobes by cutting through the connective isthmus. Remove any debris from 
the thymic lobes making certain not to damage the capsule, and cut the thymus into the 
appropriate number of sections for transplantation.  
 
1.4.1) Thymi obtained from newborn mice should be left un-manipulated and can be used for 
a maximum of two recipient mice (1 lobe per recipient). 
 
1.4.2) Thymi obtained from adult mice can be used to transplant into a maximum of 4-6 
recipient mice. Using a pair of forceps, carefully grasp one adult thymic lobe, as shown in 
Fig.A1.1, cut the thymus into three equal sections using surgical scissors.  
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1.5) Repeat steps 1.3 – 1.4 for each donor mouse. In order to limit the time thymi are 
exposed, prepare 1 donor thymus at a time. 
A1.3.2. Thymus Implantation Under the Kidney Capsule 
2.1) Assemble the pre-sterilized equipment listed in Table A1.1. Proper aseptic technique 
should be utilized during the course of the procedure to prevent exposing transplant-
recipients to contaminated tools or reagents.  
 
2.2) Prior to transplantation, weigh and tag each recipient mouse. 
 
2.3) Set up the dissecting microscope and anesthesia circuit in the laminar flow hood. 
 
2.4) Using an electric razor, shave the left side of the recipient mouse and ensure no hair 
remains around the area used to make the incision. 
 
2.5) Turn on isofluorane vaporizer and anesthetize the mouse using a dose of between 1-2%. 
Ascertain proper anesthetization prior to starting the surgical procedure by checking for an 
absence of reflex following toe pinch.   
 
2.6) After the mouse is properly anesthetized, apply veterinary ointment to the eyes of the 
mouse to prevent dryness and prepare the mouse for transplantation as follows:  
 
2.6.1) Position the mouse under the dissecting microscope in a right lateral recumbent 
position so that the shaved side is facing up. Starting in the center of the surgical area, 
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dispense in a circular motion using a disposable transfer pipette 70% ethanol, followed by 
povidone-iodine. Repeat the ethanol/betadine treatment 3 times prior to making an incision.  
 
2.6.2) Using dissecting scissors make a 1-2 cm flank incision directly above the kidney.  
 
2.6.3) Using medium forceps grasp connective tissue adjacent to the kidney and gently lift 
the kidney so that it lies atop the musculature. To keep the kidney exposed and in place over 
the musculature, insert one arm of medium forceps underneath the kidney, paying special 
attention not to disrupt the renal ilium.   
 
2.6.4) In order to prevent tissue desiccation, irrigate the kidney with sterile 1x PBS (pH 7.4) 
during each step until manipulation of the kidney and kidney capsule is complete.  
 
2.7) Using fine forceps pinch and lift the capsule near the edge of the kidney most distal to 
the adrenal glands to separate it from the kidney.  
 
2.8) Use an 18-gauge needle to make an incision large enough to insert the prepared piece of 
donor thymus (Fig. A1.2A). Make certain to keep the capsular incision as small as possible to 
prevent dislocation of the graft over time.  
  
2.9) While keeping the capsule pulled away from the kidney, use a second pair of fine 
forceps to insert the graft underneath the capsule and push the thymus as far forward from the 
capsular incision as possible (Fig. A1.2B).  
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2.10) Remove the forceps from underneath the kidney, and gently return the kidney back into 
place through the incision.  
 
2.11) Close the musculature by suturing the peritoneal wall and applying betadine once 
closed. After suturing is complete, apply wound clips to close the dermis and apply betadine 
to the surrounding area. 
  
2.12) Return the mouse to a cage that has been warmed using a heat lamp. 
 
2.13) Monitor each post-operative mouse until it regains full consciousness and mobility and 
do not place mice that have not recovered following anesthesia into a cage with other 
animals. 
 
2.14) Treat mice with post-operative pain management drugs as needed. Provide mice with 
post-operative analgesics such as acetaminophen in the drinking water at a concentration of 
1.6 mg/mL.  
 
2.15) Repeat steps 2.3 – 2.9 for each recipient mouse.  
 
2.16) Return mice should to normal activity within an hour following surgery. Monitor the 
post-operative weight, motor skills, as well as the drinking and feeding activity of each 
mouse to determine complications arising as a result of the transplant procedure. NOTE: 
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Post-operative weight loss, when compared to pre-operative weight, as well as altered 
mobility or failure to eat or drink may indicate complications. 
 
2.17) Monitor T cell reconstitution in peripheral blood by bleeding mice via tail nick 
followed by separation of lymphocytes using Lympholyte cell separation media according to 
the manufacturer’s specifications. Accomplish T cell characterization by staining 
lymphocytes with the fluorescently conjugated T cell markers CD3, CD4, and CD8, as well 
as a live dead discriminator such as a fluorescently activated succinimidyl ester [8]. Analysis 
as shown in figure A1.3 can be accomplished via gating on singlets, live cells, and CD3 
positive cells. 
A1.4 Results 
The success of this procedure is dependent on minimal surgical trauma as well as the 
accurate positioning of the graft underneath the kidney capsule. The thymic graft should be 
cut to ensure appropriately sized thymic sections for subsequent transplantation as shown in 
Fig.A1.1. Following the schematic in Fig.A1.1, thymi from newborn or adult mice can be 
used for successful subcapsular transplantation with consistent and reproducible T cell 
engraftment results. As mentioned, appropriate positioning of the graft under the kidney 
capsule is important in maintaining long-term survival, function, and vascularization of the 
graft. As seen in Fig. A1.2, the thymic graft should be placed atop the kidney, closest to the 
adrenal glands (anterior of kidney), on the opposite end from the capsular incision (posterior 
of kidney). A successful thymic transplant, when coupled with an appropriate hematopoietic 
environment, can remain productive in excess of 30 weeks [7]. 
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Following transplantation, engraftment is assessed by flow cytometric analyses of T 
cells obtained from peripheral blood.  Fig. A1.3 and Table A1.2 demonstrate the typical level 
of T cell engraftment observed in organs and peripheral blood in a transplant recipient 6 
weeks post-transplantation. Using this technique, our group has previously shown the 
kinetics of CD4+ and CD8+ T cell reconstitution in peripheral blood over time in transplant 
recipients of newborn and adult thymi. Briefly, circulating T cells can be observed in the 
periphery within one week post-surgery and CD4+ and CD8+ T cell numbers continue to 
increase until the peripheral T cell compartment is fully reconstituted at 5-6 weeks post 
transplantation [7].  
A1.5 Discussion 
Events regulating thymic selection are poorly understood. Recent studies have 
demonstrated ontogenic changes in the efficiency of selection. Coupling this approach with 
different transgenic thymus donor and recipient mice will further facilitate studies to identify 
the events and parameters that regulate thymic selection. Notably, thymic transplantation is 
used for the treatment and management of T cell and thymic disorders seen for instance in 
athymic infants lacking functional T cells and in patients with DiGeorge syndrome, 
characterized by thymic hypoplasia or thymic aplasia [9, 10]. Thymus transplantation, like 
most organ transplantation, is not free of complications, which are mostly due to transplant 
tolerance-related complications and development of autoimmune pathologies [11, 12]. These 
issues, coupled with the need to better understand and characterize mechanisms involved in 
thymocyte tolerance induction led to the development of this method. The protocol described 
herein experimentally models thymic transplantation and demonstrates that efficient T cell 
reconstitution is obtained in recipients. 
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There are several key points to note in the protocol. It is necessary to be adept at 
surgery and aseptic technique prior to performing the transplantation surgery. Adherence to 
this will help minimize trauma, the time the mouse is anesthetized, and recovery time so that 
100% post-surgery survival rate can be readily obtained. When preparing the donor thymus, 
it is imperative that the organ is kept on wet ice to minimize cell death. In addition the 
thymic lobes need to be cut to appropriate sized fragments to permit implantation without 
tearing the kidney capsule. Similarly, care is required to prevent any injury to the kidney 
upon making the incision of the renal capsule. Placement of the thymic graft underneath the 
kidney capsule is another important step in the process.  Injury to the kidney or tearing of the 
renal capsule can be avoided with gentle handling, using appropriate fine-tipped surgical 
tools, and sufficient practice. One possibility to note is that successful T cell engraftment 
may also be achieved by implanting thymic lobes at sites other than under the kidney 
capsule, for instance at a subcutaneous site. The kidney however provides an ideal 
environment to receive thymic grafts due to a high level of vascularization, which promotes 
both graft survival as well as efficient T cell trafficking following thymic selection. 
A distinct advantage of the above thymus transplant protocol is the technical ease in 
determining T cell engraftment. Using flow cytometry, success of the procedure is 
qualitatively and quantitatively assessed by measuring the frequency of T cells in peripheral 
blood. In addition to observing mature T cells in the blood, T cell engraftment is detected in 
various lymphoid organs. The latter permits further study of the expansion, activation, and 
differentiation of peripheral T cells in various host genetic environments under physiological 
conditions. One caveat that investigators may consider when interpreting results is that 
following thymic engraftment into an immunodeficient recipient, newly selected T cells will 
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undergo lymphopenic expansion in the periphery. Although this rapid expansion will not 
alter thymic selection events, it may lead to preferential expansion of distinct T cell subsets 
in peripheral tissues.  
This protocol is widely applicable for studying mechanisms regulating T cell 
development and homeostasis in a variety of pathologies. For example, this approach can be 
used to study FoxP3 regulatory T cell generation and development, as well as T cell renewal 
and export from the thymus in in vivo models of persistent viral, fungal, or bacterial infection 
[7, 13-15]. In summary, this article describes a method of thymus transplantation that entails 
minimal manipulation of donor tissue, and a high success rate once the technique has been 
mastered. 
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Figure A1.1: Preparation of thymic lobes and sections from donor newborn and adult 
mice. Donor thymi are excised from 1 day-old (N.B.) and 4 week-old (Adult). Dashed lines 
are presented as a guide for preparing the maximum number of sections from one donor 
organ for subsequent transplantation.  
  
N.B. 
thymus
Adult 
thymus
mm
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Fine Dissecting forceps 
Medium Dissecting forceps (2) 
Fine dissecting forceps (curved tip) 
Betadine Solution 
70% Ethanol  
18 gauge needle 
Dissecting microscope w/light source 
Disposable transfer pipettes (2) 
Drugs for pain management: Acetaminophen 
Sterile wipes  
Heat lamp 
Electric razor 
Isoflurane and isoflurane vaporizer 
Sutures (fast absorbing, plain gut) 
Dissecting Scissors  
9 mm Stainless Steel Wound clips 
Wound clip removal tool 
Sterile 1x PBS 
60 mm Dish 
Table A1.1: Materials needed during surgical thymic transplantation. List of necessary 
materials used to implant the thymus underneath the kidney capsule of the recipient mouse. 
The quantity of specified materials is listed in parenthesis.  
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Figure A1.2: Position of capsular incision and placement of thymic graft. An 
appropriately sized section prepared from the donor thymus is inserted into the subcapsular 
space created by a small incision in the renal capsule at the posterior end of the kidney (A). 
Anterior to the kidney, closest to the adrenal glands (not pictured) and at the opposite end 
from the capsular incision, is the optimal position for the graft that is inserted underneath the 
capsule as shown in B.  
  
Position of graft 
underneath kidney 
capsule
Anterior
Incision of renal 
capsule
Posterior
A.
B.
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Figure A1.3: Determining successful engraftment via T cell reconstitution in peripheral 
blood and lymphoid organs. Flow cytometric data are representative of T cell reconstitution 
observed 6 weeks post-transplantation in a scid recipient of a N.B. thymic graft. Similar 
levels of T cell engraftment are observed in peripheral blood, spleen, pancreatic lymph node 
(PLN), and the mesenteric lymph node (MLN) following successful transplantation of a 
thymic graft.  
  
 
Blood Spleen PLN MLN
CD4
C
D
8
17%
81%
26%
72%
22%
76%
19%
79%
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Total Number of CD4 T 
cells 
Total Number of CD8 T 
cells 
Blood 1,652 cells/υl 351 cells/υl 
Spleen 11,546,617 4,203,299 
PLN 1,241,789 364,918 
MLN 2,182,266 532,059 
Table A1.2: Total number of T cells present in peripheral blood and lymphoid organs 
of a thymic transplant recipient. Total numbers of CD4+ and CD8+ T cells recovered from 
the organs as well as peripheral blood of a newborn thymic transplant recipient 6 weeks post-
transplantation.  These numbers are representative of CD4+ and CD8+ T cell cellularity that is 
typically observed in successful newborn and adult thymic transplant recipients.  
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